Antisense modulation of pepck-cytosolic expression

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-cytosolic. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-cytosolic. Methods of using these compounds for modulation of PEPCK-cytosolic expression and for treatment of diseases associated with expression of PEPCK-cytosolic are provided.

Description

FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of PEPCK-cytosolic. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding PEPCK-cytosolic. Such oligonucleotides have been shown to modulate the expression of PEPCK-cytosolic.

BACKGROUND OF THE INVENTION

Gluconeogenesis is the metabolic pathway for the biosynthesis of glucose from non-carbohydrate precursors including pyruvate, lactate, and citric acid cycle intermedates. This pathway occurs predominantly in the liver and to a lesser extent in the kidney and is triggered by a fall in blood glucose concentration. Gluconeogenesis meets the needs of the body for glucose when there is insufficient intake of carbohydrates in the diet. It is also critical to the maintenance of a continuous energy supply, in the form of glucose, to red blood cells and tissues of the central nervous system, which do not undergo gluconeogenesis. In addition, gluconeogenesis represents a mechanism by which products of metabolism from other tissues are cleared from the blood and converted back into glucose. Under fasting conditions glucose production through this pathway maintains the basal glucose concentrations necessary to sustain primary physiologic functions. The gluconeogenic pathway is essentially glycolysis (the breakdown of glucose received predominantly from the diet) in reverse. There are four enzymes necessary to bypass the thermodynamically unfavorable steps of glycolysis. These enzymes are pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase, and glucose-6-phosphatase. The rate-limiting step of gluconeogenesis is catalyzed by phosphoenolpyruvate carboxykinase and this enzyme has been well characterized in several species. Two forms (isozymes) of the enzyme have been isolated and the total enzyme activity displayed in humans is equally divided between the cytosolic and mitochondrial forms (Hanson and Patel, Adv. Enzymol. Relat. Areas Mol. Biol., 1994, 69, 203-281).

Cytosolic phosphoenolpyruvate carboxykinase (also known as PCK1, cyPCK and PEPCK-C) is expressed predominantly in liver where it acts in the gluconeogenic pathway and in kidney where it acts in the gluconeogenic pathway as well as being glyceroneogenic and ammoniagenic (Hanson and Reshef, Annu. Rev. Biochem., 1997, 66, 581-611). PEPCK-cytosolic also exhibits significant expression in white and brown adipose tissue, lactating mammary gland and the small intestine where it is thought to supply glycerol for triglyceride synthesis (glyceroneogenesis) in these tissues (Hanson and Reshef, Annu. Rev. Biochem., 1997, 66, 581-611).

Studies using transgenic mice have shown that different cis acting elements are required to drive the expression of PEPCK-cytosolic in hepatocytes, renal tubule epithelial cells and adipocytes (Beale et al., Faseb J., 1992, 6, 3330-3337).

The overall expression of PEPCK-cytosolic is controlled entirely at the level of transcription by a wide variety of physiological stimuli including dietary carbohydrate, hormones, and cellular intermediates (Hanson and Patel, Adv. Enzymol. Relat. Areas Mol. Biol., 1994, 69, 203-281). It is expressed in the periportal region of the liver and is therefore sensitive to oxygen concentration. Studies of rat hepatocytes demonstrated that the glucagon-dependent activation of the PEPCK-cytosolic gene is modulated by oxygen and that this process is mediated by hydrogen peroxide (Kietzmann et al., Kidney Int., 1997, 51, 542-547; Kietzmann et al., FEBS Lett., 1996, 388, 228-232). Other factors have also been shown to impair the glucagon-induced increase in PEPCK-cytosolic including interleukin-1-beta, tumor necrosis factor alpha and interleukin-6 (Christ and Nath, Biochem. J., 1996, 320, 161-166; Christ et al., Hepatology, 1997, 26, 73-80).

In the liver, PEPCK-cytosolic is negatively regulated by insulin and has therefore been considered a potential contributing factor to hyperglycemia in diabetics (Sutherland et al., Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1996, 351, 191-199). Studies using various kinase inhibitors demonstrated a link between PEPCK-cytosolic gene regulation by insulin and the protein kinase phosphatidylinositol-3-kinase (PI3-kinase). In these studies, it was shown that insulin inhibition of PEPCK-cytosolic gene expression requires PI3-kinase but that the signal is not mediated by MAP kinases nor transmitted through protein kinase B or protein kinase C (Agati et al., J. Biol. Chem., 1998, 273, 18751-18759; Sutherland et al., Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1996, 351, 191-199).

PEPCK-cytosolic gene expression is also sensitive to other regulatory stimuli including cell volume. It has been shown that in rat and human hepatocytes, changes in cell volume alter the rate of transcription and mRNA stability of PEPCK-cytosolic (Kaiser, Am. J. Physiol., 1998, 274, G509-517).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of PEPCK-cytosolic and to date, strategies aimed at investigating PEPCK-cytosolic function have involved the use of chemical inhibitors and transgenic mice.

Consequently, there remains a long felt need for agents capable of effectively inhibiting PEPCK-cytosolic function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of PEPCK-cytosolic expression.

SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding PEPCK-cytosolic, and which modulate the expression of PEPCK-cytosolic. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of PEPCK-cytosolic in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of PEPCK-cytosolic by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding PEPCK-cytosolic, ultimately modulating the amount of PEPCK-cytosolic produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding PEPCK-cytosolic. As used herein, the terms “target nucleic acid” and “nucleic acid encoding PEPCK-cytosolic” encompass DNA encoding PEPCK-cytosolic, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as “antisense”. The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of PEPCK-cytosolic. In the context of the present invention, “modulation” means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. “Targeting” an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding PEPCK-cytosolic. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5′-AUG (in transcribed mRNA molecules; 5′-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the “AUG codon,” the “start codon” or the “AUG start codon”. A minority of genes have a translation initiation codon having the RNA sequence 5′-GUG, 5′-UUG or 5′-CUG, and 5′-AUA, 5′-ACG and 5′-CUG have been shown to function in vivo. Thus, the terms “translation initiation codon” and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, “start codon” and “translation initiation codon” refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding PEPCK-cytosolic, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or “stop codon”) of a gene may have one of three sequences, i.e., 5′-UAA, 5′-UAG and 5′-UGA (the corresponding DNA sequences are 5′-TAA, 5′-TAG and 5′-TGA, respectively). The terms “start codon region” and “translation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation initiation codon. Similarly, the terms “stop codon region” and “translation termination codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation termination codon.

The open reading frame (ORF) or “coding region,” which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5′ untranslated region (5′UTR), known in the art to refer to the portion of an mRNA in the 5′ direction from the translation initiation codon, and thus including nucleotides between the 5′ cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3′ untranslated region (3′UTR), known in the art to refer to the portion of an mRNA in the 3′ direction from the translation termination codon, and thus including nucleotides between the translation 3termination codon and 3′ end of an mRNA or corresponding nucleotides on the gene. The 5′ cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5′-most residue of the mRNA via a 5′—5′ triphosphate linkage. The 5′ cap region of an mRNA is considered to include the 5′ cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5′ cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as “introns,” which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as “exons” and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intronexon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease.

Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, “hybridization” means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. “Complementary,” as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2′, 3′ or 5′ hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3′ to 5′ phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages.

As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones;

sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH 2 component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and

5,719,262, each of which is herein incorporated by reference.

Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH 2 —NH—O—CH 2 —, —CH 2 —N(CH 3 )—O—CH 2 — [known as a methylene (methylimino) or MMI backbone], —CH 2 —O—N(CH 3 )—CH 2 —, —CH 2 —N(CH 3 )—N(CH 3 )—CH 2 — and —O—N(CH 3 )—CH 2 —CH 2 —[wherein the native phosphodiester backbone is represented as —O—P—O—CH 2 —] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C 1 to C 10 alkyl or C 2 to C 10 alkenyl and alkynyl. Particularly preferred are O[(CH 2 ) n O] m CH 3 , O(CH 2 ) n OCH 3 , O(CH 2 ) n NH 2 , O(CH 2 ) n CH 3 , O (CH 2 ), ONH 2 and O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2′ position: C 1 to C 10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 21 NO 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy (2′—O—CH 2 CH 2 OCH 3 , also known as 2′—O—(2-methoxyethyl) or 2′—MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH 2 ) 2 ON(CH 3 ) 2 group, also known as 2′—DMAOE, as described in examples hereinbelow, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′—O—dimethylaminoethoxyethyl or 2 1 -DMAEOE), i.e., 2′—O—CH 2 —O—CH 2 —N(CH 2 ) 2 , also described in examples hereinbelow.

Other preferred modifications include 2′-methoxy (2′—O—CH 3 ), 2′-aminopropoxy (2′—OCH 2 CH 2 CH 2 NH 2 ) and 2′-fluoro (2′—F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and U.S. Pat. No. 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. “Chimeric” antisense compounds or “chimeras,” in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term “prodrug” indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 to Imbach et al. ,3. The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., “Pharmaceutical Salts,” J. of Pharma Sci., 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a “pharmaceutical addition salt” includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of PEPCK-cytosolic is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding PEPCK-cytosolic, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding PEPCK-cytosolic can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of PEPCK-cytosolic in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2′-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in -Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems , Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences , Mack Publishing Co., Easton, Pa., 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in Pharmaceutical Dosage Forms , Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and triglycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term “liposome” means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274). One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., Journal of Drug Targeting, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., Antiviral Research, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasomem II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. S.T.P. Pharma. Sci., 1994, 4, 6, 466).

Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G M1 . or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. ( Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside G M1 , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. ( Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G M1 or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. ( Bull. Chem. Soc. Jpn., 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C 12 15G, that contains a PEG moiety. Illum et al. ( FEBS Lett., 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klibanov et al. ( FEBS Lett., 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. ( Biochimica et Biophysica Acta, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 Bl and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Pat. No. 5,540,935 (Miyazaki et al.) and U.S. Pat. No. 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Pat. No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the “head”) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or “surface-active agents”) are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C 1-10 alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term “bile salts” includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone. Carriers Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, “carrier compound” or “carrier” can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4′ isothiocyano-stilbene-2,2′-disulfonic acid (Miyao et al., Antisense Res. Dev., 1995, 5, 115-121; Takakura et al., Antisense & Nucl. Acid Drug Dev., 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC 50 s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2′-alkoxy amidites

2′-Deoxy and 2′-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling Va.). Other 2′-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Pat. No. 5,506,351, herein incorporated by reference. For oligonucleotides synthesized ,using 2′-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2′-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., Nucleic Acids Research, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling Va. or ChemGenes, Needham Mass.).

2′-Fluoro amidites

2′-Fluorodeoxyadenosine amidites

2′-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., J. Med. Chem., 1993, 36, 831-841] and U.S. Pat. No. 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2′-deoxy-2′-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2′-alpha-fluoro atom is introduced by a S N 2-displacement of a 2′-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3′,5′-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5′-dimethoxytrityl-(DMT) and 5′-DMT-3′-phosphoramidite intermediates.

2′-Fluorodeoxyguanosine

The synthesis of 2′-deoxy-2′-fluoroguanosine was accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective 0-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5′-DMT- and 5′-DMT-3′-phosphoramidites.

2′-Fluorouridine

Synthesis of 2′-deoxy-2′-fluorouridine was accomplished by the modification of a literature procedure in which 2,2′-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% c hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5′-DMT and 5′-DMT-3′ phosphoramidites.

2′-Fluorodeoxycytidine

2′-deoxy-2′-fluorocytidine was synthesized via amination of 2′-deoxy-2′-fluorouridine, followed by selective protection to give N4-benzoyl-2′-deoxy-2′-fluorocytidine. Standard procedures were used to obtain the 5′-DMT and 5′-DMT-3′ phosphoramidites.

2′-O-(2-Methoxyethyl) modified amidites

2′-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., Helvetica Chimica Acta, 1995, 78, 486-504.

2,2′-Anhydro[l-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured 2into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60° C. at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4° C.).

2′-O-Methoxyethyl-5-methyluridine

2,2′-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160° C. After heating for 48 hours at 155-160° C., the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH 3 CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH 2 Cl 2 /acetone/MeOH (20:5:3) containing 0.5% Et 3 NH. The residue was dissolved in CH 2 Cl 2 (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine

2′-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH 3 CN (200 mL). The residue was dissolved in CHCl 3 (1.5 L) and extracted with 23500 mL of saturated NaHCO 3 and 2×500 mL of saturated NaCl. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et 3 NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3′-O-Acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine

2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35° C. The residue was dissolved in CHCl 3 (800 mL) and extracted with 2×200 mL of saturated sodium bicarbonate and 2×200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl 3 . The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3′-O-Acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3′-O-acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH 3 CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH 3 CN (1 L), cooled to −5° C. and stirred for 0.5 h using an overhead stirrer. POCl 3 was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10° C., and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1×300 mL of NaHCO 3 and 2×300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine

A solution of 3′-O-acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH 4 OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2×200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH3 gas was added and the vessel heated to 100° C. for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine

2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl 3 (700 mL) and extracted with saturated NaHCO 3 (2×300 mL) and saturated NaCl (2×300 mL), dried over MgSO 4 and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et 3 NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine-3′-amidite

N4-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH 2 Cl 2 (1 L).

Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO 3 (1×300 mL) and saturated NaCl (3×300 mL). The aqueous washes were back-extracted with CH 2 Cl 2 (300 mL), and the extracts were combined, dried over MgSO 4 and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

2′-O-(Aminooxyethyl) nucleoside amidites and 2′-O-(dimethylazinooxyethyl) nucleoside amidites

2′-(Dimethylaminooxyethoxy) nucleoside amidites

2′-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2′-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5′-O-tert-Butyldiphenylsilyl-O 2 -2′-anhydro-5-methyluridine

O 2 -2′-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0 g, 0.416 mmol), dimethylaminopyridine (0.66 g, 0.013 eq, 0.0054 mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8 g, 119.0 mL, 1.1 eq, 0.458 mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2×1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600 mL) and the solution was cooled to −10° C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3×200 mL) and dried (40° C., 1 mm Hg, 24 h) to 149 g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution aof hydrogen gas subsided. 5′-O-tert-Butyldiphenylsilyl-O 2 -2′-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160° C. was reached and then maintained for 16 h (pressure <100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1 mm Hg) in a warm water bath (40-100° C.) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84 g, 50%), contaminated starting material (17.4 g) and pure reusable starting material 20 g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine

5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine (20 g, 36.98 mmol) was mixed with triphenylphosphine (11.63 g, 44.36 mmol) and N-hydroxyphthalimide (7.24 g, 44.36 mmol). It was then dried over P 2 O 5 under high vacuum for two days at 40° C. The reaction mixture was flushed with argon and dry THF (369.BmL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98 mL, 44.36 mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine (3.lg, 4.5 mmol) was dissolved in dry CH 2 Cl 2 (4.5 mL) and methylhydrazine (300 mL, 4.64 mmol) was added dropwise at −10° C. to 0° C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH 2 Cl 2 and the combined organic phase was washed with water, brine and dried over anhydrous Na 2 SO 4 . The solution was concentrated to get 2′-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5 mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was strirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5,-0-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5′-O-tort-Butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77 g, 3.12 mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6 mL). Sodium cyanoborohydride (0.39 g, 6.13 mmol) was added to this solution at 10° C. under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10° C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH 2 Cl 2 ). Aqueous NaHCO 3 solution (5%, 10 mL) was added and extracted with ethyl acetate (2×20 mL). Ethyl acetate phase was dried over anhydrous Na 2 SO 4 , evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6 mL). Formaldehyde (20% w/w, 30 mL, 3.37 mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10° C. in an ice bath, sodium cyanoborohydride (0.39 g, 6.13 mmol) was added and reaction mixture stirred at 10° C. for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO 3 (25 mL) solution was added and extracted with ethyl acetate (2×25 mL). Ethyl acetate layer was dried over anhydrous Na 2 SO 4 and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH 2 Cl 2 to get 5′-O-tert-butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6 g, 80%).

2′-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91 mL, 24.Ommol) was dissolved in dry THF and triethylamine (1.67 mL, 12 mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5,-0-tert-butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40 g, 2.4 mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH 2 Cl 2 ). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH 2 Cl 2 to get 2′-O-(dimethylaminooxyethyl)-5-methyluridine (766 mg, 92.5%). 5′-O-DKT-2′-O-(dimethylaminooxyethyl)-5-methyluridine 2′-O-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P 2 O 5 under high vacuum overnight at 40° C. It was then co-evaporated with anhydrous pyridine (20 mL). The residue obtained was dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol), 4,4′-dimethoxytrityl chloride (880 mg, 2.60 mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH 2 Cl 2 (containing a few drops of pyridine) to get 5′-O-DMT-2′-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13 g, 80%).

5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL). To the residue N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and dried over P 2 O 5 under high vacuum overnight at 40° C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N 1 ,N 1 -tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70 mL) and washed with 5% aqueous NaHCO 3 (4OmL). Ethyl acetate layer was dried over anhydrous Na 2 SO 4 and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04 g, 74.9%).

2′-(Aminooxyethoxy) nucleoside amidites

2′-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2′-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2′-O-aminooxyethyl guanosine analog may be obtained by selective 2′-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2′-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3′-O-isomer. 2′-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2′-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 Al 940203.) Standard protection procedures should afford 2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-0-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-0-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2′-dimethylaminoethoxyethoxy (2′-DMAEOE) nucleoside amidites

2′-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2′-O-dimethylaminoethoxyethyl, i.e., 2′—O—CH 2 —O—CH 2 —N (CH 2 ) 2, or 2′-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2′-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O2,2′-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155° C. for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3×200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5′-O-dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy) ethyl)]-5-methyl uridine

To 0.5 g (1.3 imol) of 2′-O-[2(2-N,N-dimethylamino-ethoxy)ethyl)]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH 2 Cl 2 (2×200 mL). The combined CH 2 Cl 2 layers are washed with saturated NaHCO 3 solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH 2 Cl 2 :Et 3 N (20:1, v/v, with 1% triethylamine) gives the title compound.

5′-O-Dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl uridine-3′-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5′-O-dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH 2 Cl 2 (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55° C. (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution.

Phosphinate oligonucleotides are prepared as described in U.S. Pat. No. 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 4,469,863, herein incorporated by reference.

3′-Deoxy-3′-methylene phosphonate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3′-Deoxy-3′-amino phosphoramidate oligonucleotides are prepared as described in U.S. Pat. No. 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Pat. No. 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Pat. No. 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Pat. Nos. 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the “gap” segment of linked nucleosides is positioned between 5′ and 3′ “wing” segments of linked nucleosides and a second “open end” type wherein the “gap” segment is located at either the 3′ or the 5′ terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as “gapmers” or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as “hemimers” or “wingmers”.

[2′-O-Me]—[2′-deoxy]—[2′-O-Me]Chimeric

Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2′-O-alkyl phosphorothioate and 2′-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2′-deoxy-5′-dimethoxytrityl-3′-O-phosphoramidite for the DNA portion and 5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite for 5′ and 3′ wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2′-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2′ positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to ½ volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2′-O-(2-Methoxyethyl)]—[2′-deoxy]—[2′-O-(Methoxyethyl)] Chimeric Phosphorothioate

Oligonucleotides

[2′-O-(2-methoxyethyl)]—[2′-deoxy]—[-2′-O-(methoxy-ethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2′-O-methyl chimeric oligonucleotide, with the substitution of 2′-O-(methoxyethyl) amidites for the 2′-O-methyl amidites.

[2′-O-(2-Methoxyethyl)Phosphodiester]—[2′-deoxy Phosphorothioate]—[2′-O-(2-Methoxyethyl)

Phosphodiester] Chimeric Oligonucleotides

[2′-O-(2-methoxyethyl phosphodiester]—[2′-deoxy phosphorothioate]—[2′-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2′-O-methyl chimeric oligonucleotide with the substitution of 2′-O-(methoxyethyl) amidites for the 2′-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Pat. No. 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55° C. for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by 31 P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis—96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, Calif., or Pharmacia, Piscataway, N.J.). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH 4 OH at elevated temperature (55-60° C.) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

Oligonucleotide Analysis—96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 6 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville Md.). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville Md.) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville Md.). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville Md.) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

HepG2 cells:

The human hepatoblastoma cell line HepG2 was obtained from the American Type Culure Collection (Manassas, Va.). HepG2 cells were routinely cultured in Eagle's MEM supplemented with 10% fetal calf serum, non-essential amino acids, and 1 mM sodium pyruvate (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Primary mouse hepatocytes

Primary mouse hepatocytes were prepared from CD-1 mice purchased from Charles River Labs. Primary mouse hepatocytes were routinely cultured in Hepatoyte Attachment Media (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco/Life Technologies, Gaithersburg, Md.), 250nM dexamethasone (Sigma), 10 nM bovine insulin (Sigma). Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 10000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates =and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 gL OPTI-MEMTM-1 reduced-serum medium (Gibco BRL) and then treated with 130 gL of OPTI-MEMTM-1 containing 3.75 μg/mL LIPOFECTINTM (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 1, a 2′-O-methoxyethyl gapmer (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, ATGCATTCTGCCCCCAAGGA, SEQ ID NO: 2, a 2′-O-methoxyethyl gapmer (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

Example 10

Analysis of oligonucleotide inhibition of PEPCK-cytosolic expression

Antisense modulation of PEPCK-cytosolic expression can be assayed in a variety of ways known in the art. For example, PEPCK-cytosolic mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be “multiplexed” with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only (“single-plexing”), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

Protein levels of PEPCK-cytosolic can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to PEPCK-cytosolic can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+mRNA isolation

Poly(A)+mRNA was isolated according to Miura et al., Clin. Chem., 1996, 42, 1758-1764. Other methods for poly(A)+mRNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 60 μL lysis buffer (10 mM Tris-HC1, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μL of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine Calif.). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μL of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μL of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70° C. was added to each well, the plate was incubated on a 90° C. hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

Total mRNA was isolated using an RNEASY 96 Tm kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 100 μL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVACT manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μL water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia Calif.). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of PEPCK-cytosolic mRNA Levels

Quantitation of PEPCK-cytosolic mRNA levels was determined by real-time quantitative PCR using the ABI PRISMTM 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, Calif.) is attached to the 5′ end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, Calif. or PE-Applied Biosystems, Foster City, Calif.) is attached to the 3′ end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3′ quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5′-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISMT 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, Calif. RT-PCR reactions were carried out by adding 25 μL PCR cocktail (1× TAQMAN™ buffer A, 5.5 mM MgCl 2 , 300 μM each of DATP, dCTP and dGTP, 600 μM of dUTP, 100 μM each of forward primer, reverse primer, and probe, 20 Units RNAse inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MULV reverse transcriptase) to 96 well plates containing 25 μL poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

Probes and primers to human PEPCK-cytosolic were designed to hybridize to a human PEPCK-cytosolic sequence, using published sequence information (GenBank accession number L05144, incorporated herein as SEQ ID NO:3). For human PEPCK-cytosolic the PCR primers were: forward primer: TGGGCTCACCTCTGTCGAA (SEQ ID NO: 4) reverse primer: TGCCCATCCGCGTCAT (SEQ ID NO: 5) and the PCR probe was: FAM-CTGACGGATTCGCCCTACGTGGTG-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. For human GAPDH the PCR primers were: forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7) reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the PCR probe was: 5′ JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3′ (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Probes and primers to mouse PEPCK-cytosolic were designed to hybridize to a mouse PEPCK-cytosolic sequence, using published sequence information (GenBank accession number AF009605, incorporated herein as SEQ ID NO:10). For mouse PEPCK-cytosolic the PCR primers were: forward primer: ATCCAGGGCAGCCTCGA (SEQ ID NO:11) reverse primer: AGCATTGCCTTCCACGAACT (SEQ ID NO: 12) and the PCR probe was: FAM-AGCCTGCCCCAGGCAGTGAGG-TAMRA (SEQ ID NO: 13) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. For mouse GAPDH the PCR primers were: forward primer: GGCAAATTCAACGGCACAGT (SEQ ID NO: 14) reverse primer: GGGTCTCGCTCCTGGAAGCT (SEQ ID NO: 15) and the PCR probe was: 5′ JOE-AAGGCCGAGAATGGGAAGCTTGTCATC-TAMRA 3′ (SEQ ID NO: 16) where JOE (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 14

Northern blot analysis of PEPCK-cytosolic mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOLTM (TEL-TEST “B” Inc., Friendswood, Tex.). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, Ohio). RNA was transferred from the gel to HYBOND™-N+nylon membranes (Amersham Pharmacia Biotech, Piscataway, N.J.) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST “B” Inc., Friendswood, Tex.). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKERTM UV Crosslinker 2400 (Stratagene, Inc, La Jolla, Calif.) and then robed using QUICKHYBT hybridization solution (Stratagene, La Jolla, Calif.) using manufacturer's recommendations for stringent conditions.

To detect human PEPCK-cytosolic, a human PEPCK-cytosolic specific probe was prepared by PCR using the forward primer TGGGCTCACCTCTGTCGAA (SEQ ID NO: 4) and the reverse primer TGCCCATCCGCGTCAT (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.).

To detect mouse PEPCK-cytosolic, a mouse PEPCK-cytosolic specific probe was prepared by PCR using the forward primer ATCCAGGGCAGCCTCGA (SEQ ID NO:11) and the reverse primer AGCATTGCCTTCCACGAACT (SEQ ID NO: 12). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGERTM and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, Calif.). Data was normalized to GAPDH levels in untreated controls.

Example 15

Antisense inhibition of human PEPCK-cytosolic expression by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human PEPCK-cytosolic RNA, using published sequences (GenBank accession number L05144, incorporated herein as SEQ ID NO: 3). The oligonucleotides are shown in Table 1. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human PEPCK-cytosolic mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, “N.D.” indicates “no data”.

TABLE 1
Inhibition of human PEPCK-cytosolic mRNA levels by chimeric
phosphorothioate oligonucleotides having 2′-MOE wings and a
deoxy gap
			TARGET			SEQ ID
ISI #	REGION	TARGET SEQ ID NO	SITE	SEQUENCE	% INHIB	NO
108077	5′UTR	3	10	ctcttcccgccagcaagttt	51	18
108078	5′UTR	3	50	tggatgatctcgaagggaga	0	19
108032	Start	3	103	tttctgcagagtgctgctaa	64	20
	Codon
108033	Start	3	105	catttctgcagagtgctgct	15	21
	Codon
108034	Start	3	107	ggcatttctgcagagtgctg	39	22
	Codon
108035	Start	3	109	gaggcatttctgcagagtgc	42	23
	Codon
108036	Start	3	111	aggaggcatttctgcagagt	41	24
	Codon
108037	Start	3	113	tgaggaggcatttctgcaga	40	25
	Codon
108038	Start	3	115	gctgaggaggcatttctgca	60	26
	Codon
108039	Start	3	117	cagctgaggaggcatttctg	29	27
	Codon
108040	Start	3	119	tgcagctgaggaggcatttc	40	28
	Codon
108041	Start	3	121	tttgcagctgaggaggcatt	64	29
	Codon
108042	Start	3	123	gttttgcagctgaggaggca	55	30
	Codon
108043	Coding	3	125	ccgttttgcagctgaggagg	24	31
108044	Coding	3	138	cgagaggttcaggccgtttt	70	32
108045	Coding	3	168	gctgtccaggcttccctgga	47	33
108046	Coding	3	220	gctgacacagctcagcgtta	54	34
108047	Coding	3	251	tcagagccgtcacagatgtg	46	35
108048	Coding	3	277	ggcccagaagccgcccattc	79	36
108049	Coding	3	302	ctgaggatgccctcttcctc	70	37
108050	Coding	3	327	gcagttgtcatacttcttca	0	38
108051	Coding	3	371	ctttcgatcctggccacatc	57	39
108052	Coding	3	397	gctcttgggtgacgataacc	75	40
108053	Coding	3	439	gctggctgaggcctgttttg	59	41
108054	Coding	3	465	atcctcctctgacatccagc	48	42
108055	Coding	3	493	ggaacctggcattgaacgct	47	43
108056	Coding	3	523	cgtacatggtgcgacctttc	55	44
108057	Coding	3	549	cagcggccccatgctgaatg	32	45
108058	Coding	3	581	agctcgatgccgatcttcga	74	46
108059	Coding	3	612	catgctggccaccacgtagg	75	47
108060	Coding	3	642	gacgggcgtgcccatccgcg	52	48
108061	Coding	3	674	ttgacaaactccccatcgcc	7	49
108062	Coding	3	709	gtaaaggcagagggcacccc	57	50
108063	Coding	3	741	gttgcagggccagttgttga	57	51
108064	Coding	3	774	gtcaggcaggtgggcgatga	34	52
108065	Coding	3	809	ccgtacccactgccaaagga	69	53
108066	Coding	3	841	caaagcacttcttcccgagc	58	54
108067	Coding	3	876	ttcctcctctgccagccggc	88	55
108068	Coding	3	912	tatacccagaatcagcatgt	13	56
108069	Coding	3	946	ccgccaggtacttcttctca	75	57
108070	Coding	3	980	aggttggtcttcccgcaggc	56	58
108071	Coding	3	1045	tccaggcaatgtcatccccg	27	59
108072	Coding	3	1086	tgggttgatgggcccttaaat	54	60
108073	Coding	3	1158	ctggatggtcttgatggcat	0	61
108074	Coding	3	1198	cgtcgctggtctcggccaca	70	62
108075	Coding	3	1254	cgtgatggtgacgcctgaag	15	63
108076	Coding	3	1295	ggttccccatcctctgagct	11	64
108079	Coding	3	1386	aatgggaacaccttccggag	26	65
108080	Coding	3	1427	gggacaccagcaggtctacg	6	66
108081	Coding	3	1467	aaagactccatgttgccagc	83	67
108082	Coding	3	1524	gattttgcctttatgttctg	27	68
108083	Coding	3	1582	ggtatttgccgaagttgtag	39	69
108084	Coding	3	1623	tttggctgctgggtgctggg	50	70
108085	Coding	3	1663	tgtccttccggaaccagttg	44	71
108086	Coding	3	1704	ggagttctctccaaagcctg	12	72
108087	Coding	3	1744	cttttccatcgatccggttg	35	73
108088	Coding	3	1801	tcaggttcagggcatcctcc	68	74
108089	Coding	3	1842	gatgctgaaaagctccatca	61	75
108090	Coding	3	1882	tctcgatgtcttccacctcc	58	76
108091	Coding	3	1939	ggatctctctctcgatttca	63	77
108092	Stop	3	1982	tcaggccctgattacatctg	70	78
	Codon
108093	3′UTR	3	2025	ttaaaggtaaagcactcagg	53	79
108094	3′UTR	3	2058	ctactgcaccttatggattt	48	80
108095	3′UTR	3	2094	tggcgtcaatttgggaacac	53	81
108096	3′UTR	3	2123	ctgctcccggtgtggtgatg	45	82
108097	3′UTR	3	2174	ccagtgttctgtggttctta	78	83
108098	3′UTR	3	2207	aagatttcccttctcaattt	19	84
108099	3′UTR	3	2253	aatttgaacaaagtatgcat	17	85
108100	3′UTR	3	2286	aacactgaaaagatcaatgc	32	86
108105	3′UTR	3	2353	atatatatatacagctcaag	45	87
108106	3′UTR	3	2373	acacacacacacacacacac	34	88
108107	3′UTR	3	2398	tgtgcacatacatgcacaca	0	89
108108	3′UTR	3	2416	aaatatcacacagacacatg	0	90
108109	3′UTR	3	2431	acaaatacacataccaaata	16	91
108110	3′UTR	3	2451	tattttgaataacagtacat	0	92
108111	3′UTR	3	2466	caaaggtattaaatatattt	0	93
108101	3′UTR	3	2488	ggtcatcttgcccaagattt	78	94
108102	3′UTR	3	2502	aaggaaaactagtaggtcat	32	95
108103	3′UTR	3	2538	ttaagcacaatattaataac	8	96
108104	3′UTR	3	2573	tgtaaaggtaaggaacaatg	21	97

As shown in Table 1, SEQ ID NOs 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 62, 65, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 86, 87, 88, 94 and 95 demonstrated at least 25% inhibition of human PEPCK-cytosolic expression in this assay and are therefore preferred.

Example 17

Antisense inhibition of mouse PEPCK-cytosolic expression by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap.

In accordance with the present invention, a second series of oligonucleotides were designed to target different regions of the mouse PEPCK-cytosolic RNA, using published sequences (GenBank accession number AF009605, incorporated herein as SEQ ID NO: 10), and a cDNA sequence derived from the AF009605 genomic sequence using the GenBank “feature” function and incorporated herein as SEQ ID NO: 17. series of oligonucleotides were designed to target different regions of the mouse PEPCK-cytosolic RNA, using published sequences (GenBank accession number AF009605, incorporated herein as SEQ ID NO: 10, and GenBank accession number AF009605, a genomic sequence from which the cDNA was derived and is incorporated herein as SEQ ID NO: 17). The oligonucleotides are shown in Table 2. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 2 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are compposed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse PEPCK-cytosolic mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, “N.D.” indicates “no data”.

TABLE 2
Inhibition of mouse PEPCK-cytosolic mRNA levels by chimeric
phosphorothioate oligonucleotides having 2′-MOE wings and a
deoxy gap
			TARGET			SEQ ID
ISIS #	REGION	TARGET SEQ ID NO	SITE	SEQUENCE	% INHIB	NO
113362	5′UTR	10	5588	ccctgcctacctttcttcct	0	98
113336	5′UTR	10	5616	tgtatttttggagaggtgaa	0	99
113346	5′UTR	10	5639	aagaacatgagtgggcccct	0	100
113340	5′UTR	10	5651	ggaaaaccttccaagaacat	0	101
113330	5′UTR	10	5681	cacttactttactgggacgg	0	102
113351	5′UTR	10	5724	gggtattcttgtactcaccc	0	103
113333	Intron	10	6208	ctcttaagcttctcaggtgt	0	104
113341	Intron	10	6319	ggagcttgaccaggtggaca	0	105
113347	Intron	10	6414	aagtcacagggactccttca	7	106
113339	Intron	10	6690	tgggccacgctttgcagctc	0	107
113352	Intron	10	6720	gaaacagaaccagacagtgc	31	108
113338	Intron	10	6862	tttcttttgagaccaagtgt	25	109
113344	Intron	10	6999	aggcagcttaacatccacat	38	110
113334	Intron	10	7039	tgcaaagtgctgaaattaaa	0	111
113354	Intron	10	7083	tgccttttggccacgaacct	22	112
113353	Intron	10	7087	atcatgccttttggccacga	26	113
113337	Intron	10	7487	caaactcagggcctcatgca	45	114
113357	Intron	10	7532	tggtaggcctgacccagcat	0	115
113363	Coding	10	7672	accaaaggctctgcaaacaa	0	116
113331	Intron	10	8118	agggtcttcccaaaggcaga	6	117
113349	Intron	10	8416	atggacgggatcagctttag	0	118
113360	Coding	10	8597	gaagactcaccttgggcatc	0	119
113342	Intron	10	9083	gtgtgtgtgagtgtgtgtga	0	120
113358	Intron	10	9237	actctgcagttttctgcttc	29	121
113345	Intron	10	9324	ctagctcatgtcctaaagtt	0	122
113350	Intron	10	9358	caagcatcccagagttctta	22	123
113356	Intron	10	9373	ggtatgaatgcaagccaagc	0	124
113359	Intron	10	9382	agagaaggaggtatgaatgc	37	125
113355	Intron	10	9655	agccagagcacacagcctct	0	126
113332	Intron	10	9701	acgagagagataccccttag	4	127
113361	Coding	10	9725	catggttccgctgcaagaga	0	128
113364	Coding	10	9857	gatgcctcaccttcaggtct	0	129
113343	Intron	10	9938	agatcctttggaaccagctt	0	130
113335	Intron	10	10133	agttttctgttgagttaacc	0	131
113348	Intron	10	10365	ttccttccttccttcctcct	0	132
113365	3′UTR	10	11752	ataaaagtttattttgtaat	0	133
113366	3′UTR	10	11754	ctataaaagtttattttgta	0	134
113305	5′UTR	17	7	gtgttcccagagggaaggcc	0	135
113312	5′UTR	17	44	tgagcgccttgccggatttc	0	136
113327	5′UTR	17	90	ctggtgccacctttcttcct	0	137
113318	5′UTR	17	119	ttgcaatggtgtggagagag	0	138
113289	Start	17	125	gcataattgcaatggtgtgg	0	139
	Codon
113367	Start	17	133	ctgaggaggcataattgcaa	30	140
	Codon
113311	Coding	17	257	agatgtggatatactccggc	0	141
113313	Coding	17	318	atgacaccctcctcctgcat	0	142
113326	Coding	17	355	agccagccaacagttgtcat	0	143
113296	Coding	17	413	cttgggtgatgatgactgtc	0	144
113303	Coding	17	421	tctctgctcttgggtgatga	29	145
113315	Coding	17	461	ccagctggctgaggccagtt	0	146
113306	Coding	17	493	tttctcaaagtcctcttccg	0	147
113319	Coding	17	519	caccctgggaacctggcgtt	14	148
113328	Coding	17	537	atggtgcggcctttcatgca	0	149
113307	Coding	17	554	tgaatgggatgacatacatg	10	150
113302	Coding	17	557	tgctgaatgggatgacatac	0	151
113299	Coding	17	892	ctccttagccagacggctgg	0	152
113325	Coding	17	1092	cttaagttgccttgggcatc	11	153
113295	Coding	17	1119	aaaaacccgttttctgggtt	0	154
113292	Coding	17	1159	atttggatttgtcttcactg	0	155
113321	Coding	17	1210	agtctcggccacgttggtga	0	156
113304	Coding	17	1226	aaacacccccatcgctagtc	27	157
113316	Coding	17	1244	catcgatgccttcccagtaa	0	158
113301	Coding	17	1421	caaagatgataccctcaatg	0	159
113297	Coding	17	1527	tctgcagcagctgtggcctc	0	160
113329	Coding	17	1545	atgatcttgcccttgtgttc	0	161
113324	Coding	17	1600	gtatttgccgaagttgtagc	23	162
113291	Coding	17	1624	ggccatgctcagccagtggg	0	163
113294	Coding	17	1702	ccagaggaacttgccatctt	0	164
113323	Coding	17	1751	tccgcccgaacatccactcc	0	165
113308	Coding	17	1792	gtagccgatgggcgtgagct	0	166
113298	Coding	17	1947	tcaatttcgtaagggaggtc	0	167
113290	Coding	17	1978	gattctctgtttcagggctc	0	168
113368	Stop	17	1998	attgggatttacatctggct	35	169
	Codon
113314	3′UTR	17	2117	aaaggtgcttttctgatcta	15	170
113317	3′UTR	17	2122	tattaaaaggtgcttttctg	0	171
113310	3′UTR	17	2231	tggaaccaaaacccccattg	0	172
113300	3′UTR	17	2298	ttttctgtgcattttagcta	53	173
113309	3′UTR	17	2309	gctcaagtatgttttctgtg	37	174
113322	3′UTR	17	2349	cacatgctcacacagagaca	0	175
113293	3′UTR	17	2464	tacaaatttgcccaagattt	45	176
113320	3′UTR	17	2510	aaacatacatactagcaaca	9	177

As shown in Table 2, SEQ ID NOs 108, 110, 113, 114, 121, 125, 140, 145, 157, 169, 173, 174 and 176 demonstrated at least 25% inhibition of mouse PEPCK-cytosolic expression in this experiment and are therefore preferred.

Example 18

Western blot analysis of PEPCK-cytosolic protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to PEPCK-cytosolic is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGERT (Molecular Dynamics, Sunnyvale Calif.).

177 1 20 DNA Artificial Sequence Antisense Oligonucleotide 1tccgtcatcg ctcctcaggg 20 2 20 DNA Artificial Sequence Antisense Oligonucleotide 2atgcattctg cccccaagga 20 3 2657 DNA Homo sapiens CDS (122)...(1990) 3tgggaacaca aacttgctgg cgggaagagc ccggaaagaa acctgtggat ctcccttcga 60gatcatccaa agagaagaaa ggtgacctca cattcgtgcc ccttagcagc actctgcaga 120a atg cct cct cag ctg caa aac ggc ctg aac ctc tcg gcc aaa gtt gtc 169 Met Pro Pro Gln Leu Gln Asn Gly Leu Asn Leu Ser Ala Lys Val Val 1 5 10 15cag gga agc ctg gac agc ctg ccc cag gca gtg agg gag ttt ctc gag 217Gln Gly Ser Leu Asp Ser Leu Pro Gln Ala Val Arg Glu Phe Leu Glu 20 25 30aat aac gct gag ctg tgt cag cct gat cac atc cac atc tgt gac ggc 265Asn Asn Ala Glu Leu Cys Gln Pro Asp His Ile His Ile Cys Asp Gly 35 40 45tct gag gag gag aat ggg cgg ctt ctg ggc cag atg gag gaa gag ggc 313Ser Glu Glu Glu Asn Gly Arg Leu Leu Gly Gln Met Glu Glu Glu Gly 50 55 60atc ctc agg cgg ctg aag aag tat gac aac tgc tgg ttg gct ctc act 361Ile Leu Arg Arg Leu Lys Lys Tyr Asp Asn Cys Trp Leu Ala Leu Thr 65 70 75 80gac ccc agg gat gtg gcc agg atc gaa agc aag acg gtt atc gtc acc 409Asp Pro Arg Asp Val Ala Arg Ile Glu Ser Lys Thr Val Ile Val Thr 85 90 95caa gag caa aga gac aca gtg ccc atc ccc aaa aca ggc ctc agc cag 457Gln Glu Gln Arg Asp Thr Val Pro Ile Pro Lys Thr Gly Leu Ser Gln 100 105 110ctc ggt cgc tgg atg tca gag gag gat ttt gag aaa gcg ttc aat gcc 505Leu Gly Arg Trp Met Ser Glu Glu Asp Phe Glu Lys Ala Phe Asn Ala 115 120 125agg ttc cca ggg tgc atg aaa ggt cgc acc atg tac gtc atc cca ttc 553Arg Phe Pro Gly Cys Met Lys Gly Arg Thr Met Tyr Val Ile Pro Phe 130 135 140agc atg ggg ccg ctg ggc tca cct ctg tcg aag atc ggc atc gag ctg 601Ser Met Gly Pro Leu Gly Ser Pro Leu Ser Lys Ile Gly Ile Glu Leu145 150 155 160acg gat tcg ccc tac gtg gtg gcc agc atg cgg atc atg acg cgg atg 649Thr Asp Ser Pro Tyr Val Val Ala Ser Met Arg Ile Met Thr Arg Met 165 170 175ggc acg ccc gtc ctg gaa gca ctg ggc gat ggg gag ttt gtc aaa tgc 697Gly Thr Pro Val Leu Glu Ala Leu Gly Asp Gly Glu Phe Val Lys Cys 180 185 190ctc cat tct gtg ggg tgc cct ctg cct tta caa aag cct ttg gtc aac 745Leu His Ser Val Gly Cys Pro Leu Pro Leu Gln Lys Pro Leu Val Asn 195 200 205aac tgg ccc tgc aac ccg gag ctg acg ctc atc gcc cac ctg cct gac 793Asn Trp Pro Cys Asn Pro Glu Leu Thr Leu Ile Ala His Leu Pro Asp 210 215 220cgc aga gag atc atc tcc ttt ggc agt ggg tac ggc ggg aac tcg ctg 841Arg Arg Glu Ile Ile Ser Phe Gly Ser Gly Tyr Gly Gly Asn Ser Leu225 230 235 240ctc ggg aag aag tgc ttt gct ctc agg atg gcc agc cgg ctg gca gag 889Leu Gly Lys Lys Cys Phe Ala Leu Arg Met Ala Ser Arg Leu Ala Glu 245 250 255gag gaa ggg tgg ctg gca gag cac atg ctg att ctg ggt ata acc aac 937Glu Glu Gly Trp Leu Ala Glu His Met Leu Ile Leu Gly Ile Thr Asn 260 265 270cct gag ggt gag aag aag tac ctg gcg gcc gca ttt ccc agc gcc tgc 985Pro Glu Gly Glu Lys Lys Tyr Leu Ala Ala Ala Phe Pro Ser Ala Cys 275 280 285ggg aag acc aac ctg gcc atg atg aac ccc agc ctc ccc ggg tgg aag 1033Gly Lys Thr Asn Leu Ala Met Met Asn Pro Ser Leu Pro Gly Trp Lys 290 295 300gtt gag tgc gtc ggg gat gac att gcc tgg atg aag ttt gac gca caa 1081Val Glu Cys Val Gly Asp Asp Ile Ala Trp Met Lys Phe Asp Ala Gln305 310 315 320ggt cat tta agg gcc atc aac cca gaa aat ggc ttt ttc ggt gtc gct 1129Gly His Leu Arg Ala Ile Asn Pro Glu Asn Gly Phe Phe Gly Val Ala 325 330 335cct ggg act tca gtg aag acc aac ccc aat gcc atc aag acc atc cag 1177Pro Gly Thr Ser Val Lys Thr Asn Pro Asn Ala Ile Lys Thr Ile Gln 340 345 350aag aac aca atc ttt acc aat gtg gcc gag acc agc gac ggg ggc gtt 1225Lys Asn Thr Ile Phe Thr Asn Val Ala Glu Thr Ser Asp Gly Gly Val 355 360 365tac tgg gaa ggc att gat gag ccg cta gct tca ggc gtc acc atc acg 1273Tyr Trp Glu Gly Ile Asp Glu Pro Leu Ala Ser Gly Val Thr Ile Thr 370 375 380tcc tgg aag aat aag gag tgg agc tca gag gat ggg gaa cct tgt gcc 1321Ser Trp Lys Asn Lys Glu Trp Ser Ser Glu Asp Gly Glu Pro Cys Ala385 390 395 400cac ccc aac tcg agg ttc tgc acc cct gcc agc cag tgc ccc atc att 1369His Pro Asn Ser Arg Phe Cys Thr Pro Ala Ser Gln Cys Pro Ile Ile 405 410 415gat gct gcc tgg gag tct ccg gaa ggt gtt ccc att gaa ggc att atc 1417Asp Ala Ala Trp Glu Ser Pro Glu Gly Val Pro Ile Glu Gly Ile Ile 420 425 430ttt gga ggc cgt aga cct gct ggt gtc cct cta gtc tat gaa gct ctc 1465Phe Gly Gly Arg Arg Pro Ala Gly Val Pro Leu Val Tyr Glu Ala Leu 435 440 445agc tgg caa cat gga gtc ttt gtg ggg gcg gcc atg aga tca gag gcc 1513Ser Trp Gln His Gly Val Phe Val Gly Ala Ala Met Arg Ser Glu Ala 450 455 460aca gcg gct gca gaa cat aaa ggc aaa atc atc atg cat gac ccc ttt 1561Thr Ala Ala Ala Glu His Lys Gly Lys Ile Ile Met His Asp Pro Phe465 470 475 480gcc atg cgg ccc ttc ttt ggc tac aac ttc ggc aaa tac ctg gcc cac 1609Ala Met Arg Pro Phe Phe Gly Tyr Asn Phe Gly Lys Tyr Leu Ala His 485 490 495tgg ctt agc atg gcc cag cac cca gca gcc aaa ctg ccc aag atc ttc 1657Trp Leu Ser Met Ala Gln His Pro Ala Ala Lys Leu Pro Lys Ile Phe 500 505 510cat gtc aac tgg ttc cgg aag gac aag gaa ggc aaa ttc ctc tgg cca 1705His Val Asn Trp Phe Arg Lys Asp Lys Glu Gly Lys Phe Leu Trp Pro 515 520 525ggc ttt gga gag aac tcc agg gtg ctg gag tgg atg ttc aac cgg atc 1753Gly Phe Gly Glu Asn Ser Arg Val Leu Glu Trp Met Phe Asn Arg Ile 530 535 540gat gga aaa gcc agc acc aac gtc acg ccc ata ggc tac atc ccc aag 1801Asp Gly Lys Ala Ser Thr Asn Val Thr Pro Ile Gly Tyr Ile Pro Lys545 550 555 560gag gat gcc ctg aac ctg aaa ggc ctg ggg cac atc aac atg atg gag 1849Glu Asp Ala Leu Asn Leu Lys Gly Leu Gly His Ile Asn Met Met Glu 565 570 575ctt ttc agc atc tcc aag gaa ttc tgg gac aag gag gtg gaa gac atc 1897Leu Phe Ser Ile Ser Lys Glu Phe Trp Asp Lys Glu Val Glu Asp Ile 580 585 590gag aag tat ctg gtg gat caa gtc aat gcc gac ctc ccc tgt gaa atc 1945Glu Lys Tyr Leu Val Asp Gln Val Asn Ala Asp Leu Pro Cys Glu Ile 595 600 605gag aga gag atc ctt gcc ttg aag caa aga ata agc cag atg taa 1990Glu Arg Glu Ile Leu Ala Leu Lys Gln Arg Ile Ser Gln Met 610 615 620tcagggcctg agaataagcc agatgtaatc agggcctgag tgctttacct ttaaaatcat 2050taaattaaaa tccataaggt gcagtaggag caagagaggg caagtgttcc caaattgacg 2110ccacctaata atcatcacca caccgggagc agatctgaag gcacactttg atttttttaa 2170ggataagaac cacagaacac tgggtagtag ctaatgaaat tgagaaggga aatcttagca 2230tgcctccaaa aattcacatc caatgcatac tttgttcaaa tttaaggtta ctcaggcatt 2290gatcttttca gtgttttttc acttagctat gtggattagc tagaatgcac accaaaaaga 2350tacttgagct gtatatatat atgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgcatgtat 2410gtgcacatgt gtctgtgtga tatttggtat gtgtatttgt atgtactgtt attcaaaata 2470tatttaatac ctttggaaaa tcttgggcaa gatgacctac tagttttcct tgaaaaaaag 2530ttgctttgtt attaatattg tgcttaaatt atttttatac accattgttc cttaccttta 2590cataattgca atatttcccc cttactactt cttggaaaaa aattagaaaa tgaagtttat 2650agaaaag 2657 4 19 DNA Artificial Sequence PCR Primer 4tgggctcacc tctgtcgaa 19 5 16 DNA Artificial Sequence PCR Primer 5tgcccatccg cgtcat 16 6 24 DNA Artificial Sequence PCR Probe 6ctgacggatt cgccctacgt ggtg 24 7 19 DNA Artificial Sequence PCR Primer 7gaaggtgaag gtcggagtc 19 8 20 DNA Artificial Sequence PCR Primer 8gaagatggtg atgggatttc 20 9 20 DNA Artificial Sequence PCR Probe 9caagcttccc gttctcagcc 20 10 12141 DNA Mus musculus CDS (5895)...(6118) CDS (6440)...(6621) CDS (7206)...(7409) CDS (7682)...(7869) CDS (8444)...(8606) CDS (9418)...(9642) CDS (9735)...(9866) CDS (10502)...(10597) CDS (10701)...(11155) 10tccaccggga gaccccatga agtccacggt gtttctcacg atttcctggt ccgtagactc 60tgtcctgggc caccacccat ctttctctca caacccttgc atcttgatgg ggcctggcca 120gggttagatt gctttttttc tggaggcagg gtcttgtgtt gctgtgtctg gtcttgaatg 180tattatgtag ccaaggatga ccttggacac tttaatcctc ctgttttcac ctcctggatt 240gctagggatt gcaggtgttt accaccatgt ctgattcatg ggggtctggg gatcaaaccc 300agggctttgt gcatgcggcc ttcatcttgc ttcctaactg ctctattctg tatgggcttc 360tagagccctg aagacagcct gtctgaagaa accatcaggc tgatgtatta cccagcactc 420tttatctcta cctggctcag gaggtcagca acatcaggag gcgcaagagc ctggctggga 480ggctcggagt ccttggcttt aaaagattcc ttaaatgtat gctcagccgt gtctgtttgt 540ctcgtggctt ctgaggacaa gtgtaagcat gtctgggaag gtacttgtga ccgtaggacc 600cacagtttct gtctacgtca tcactattga tcctagtttg tatgcaaata cagctatcaa 660tgttgtcctc acaggacatg agctgtggac atggggatgg ggcaggtgtg tgtagcctct 720ttttctatag gaccactgag tgagtcaaac tcactatcct cctgcctctg cctcctggat 780ccatgtatgg attatactgt acatggcagg ataatctatc tatctatcta tctatctatc 840tatctatcta tctatctatc tatctaatta actctattgc tatctctctt ttgctttttt 900gagacaggtt ttctctgtat agccctggct gtcctggaac tcactctgta aaccaggctg 960gctcgaactc acagaaatcc acctgcctcc gcctcctgag tgcttaaaag catagctaaa 1020ggtgtgctcc accaccaccc agctcaggaa ttttcttaga gcattcagca ccacatgtat 1080gggctggctg tgtgattagc caagtacaga acaaaaaaaa atgaagaacc cttggttcta 1140aaaggatgac gagacatttc tctttttctt agctttctcc acctgcatgg tgcccacaac 1200ttgatagtta aaggtcacac tttctcaggc accagaatac tgacagacat cagaagatgc 1260ctgaagatgc ctggacccaa ccaaactccc tctgctgagg cacaggtcct tttcagggtc 1320gtctactggg aagggtggtc acaaaggccc aggaacagag aatatattct tccaagagcc 1380agccatgcgc atagcttctt gcgtcgtcct ggggatgagt atgcatgtgg tgtcggctgt 1440gtgtctgaca gtgaagtcct agagtcatac agagctgata aaagccctag gctcaaagtc 1500tgtggaactt ttattctgct caagaatacc agtagccatc cagccagtgt ttgctgagtg 1560aacgcatgtg attcctttct cgagcctcaa tttcctgatc tctaaattgg agaaggacaa 1620tgacgatcgg agaggaccat gggaagcccg cctttaggaa gtttgttctt cacagggctg 1680ggacccagag ggcactggag agagtgcagt taacaaatgg gactttaaat agttctttat 1740cttgtcactc aaggatacaa ccgatgagac tatcgttgag gtaacatgta gagtaggttc 1800aggaaggaat catggaagaa gacggctttg atggctgttc ttggttgtca cccttactac 1860actaggaatg gactgcaatc cagaaaggga gggcacaccc gggagagatg tttttgcttg 1920gtttgaagtg ggtgaatcca cttctagtgt ggatctttga ggtaggaaga cacaaaccac 1980aaactctttt tggtttttct ttgttttgct tttctgagac acagtttctt tgtatagccc 2040tggctgtcct gaaactggct ttgtataacc aactggccct aactcacaga ggctctgcct 2100gcctctgcct cctgagcgtt gggagacaca catcttattc cagatcttga agcaggaatt 2160cacaccttta atctgggcca caccttgtgc tggaagtcta tagagggaca cggaagaagg 2220aagcttttgc tctctgcctg atgccctccc gatgccaaca catccattcc ttcactgaca 2280ttagcaccta attcttcagg attccagcat acacagagga tcagcagaga cagtcagcct 2340tgtgggccga gcaactactg gattcttgga cttttcattc acagccagac attgttgcat 2400tagctggact gcagcctgta aatcattcca aagagtctct ctctctctct ctctctctct 2460ctctctcttt ctctctctct ctctgtgtgt ctctctctct gcctctctct ctatatatat 2520aaatatatgt gtgtgtatgt gtatgtgaaa ccatacatat acacatatac atacataaaa 2580catattcata tattaacaca cacatatata acacaaacag atagatgata gatagataga 2640tagatagata gatgatagat agatagatag atagatagat agatagatag atgatagata 2700gatgataggt agatagatag gttgatagat agatgataga tagatagatg atagatagat 2760agataggtag atagatagat gggtagatag atagatagat agatagatag atagatgata 2820gatagatagg tagatagaaa ggtagataga tagatagatg atagatagat agatgataga 2880tagatagata gatagataga tagatagata gatagataga tagatgatag atagatgata 2940gatgatagat agatagatga tagatagata gatagataga tgatagatag atgatagata 3000gatagataga tagatagata gatagataga tagatagata gatagataga tagacagaca 3060gaccatatgt tctgatactc tagagaacct tgactaatac agcagtataa ttttgagtct 3120gtttctgagt gtctggcctt cctctcttcc tctttaaagc agctttacat ctggaagcaa 3180ctgtttacag acttgacaga aagccacttt gacttaaggg aacatgagtt taaggaaccc 3240ctgagagttt agggggcctc catatgtctg tgtgagaaac cacatgggaa actcccaccc 3300tgtgggaacc catggccttg tgcctgtcct gtacaagcac tgaacgtcac ataaggtggg 3360ctgggcactt tctgggacgc ccccagcagg gcagtggcaa ccaacaccca gcagtccctt 3420tgagacttct tcaagatgaa gcagtaggaa gatgccgtgg ctcacagtgc ctcccctggg 3480aaggggacag agggctgccc agtgaggctt cttgcgggca agaaatcacc aaagacaagg 3540gaagaccgga cctcaagatg tcctcagtta ggggtgagga cacgctagcc agctttgcct 3600gactgtcctc agaatcctgc tgtatgtctc agttctccta gaggatcatg gacccccagg 3660tcattttgaa acccagtttt gacaagatcc agcatagtgt atgtggggat ttggactaat 3720tggaaggtcg tggggacccc tgctcctcca ccatcattgg gctactatat ccctcccagg 3780aggcccacag cagaggtacc ttggatgtat gtagagtgat taaaactcca gctgaattaa 3840tagtctctcc tttttttttc ccaacttaac cttccagggt taagttgaaa caaacggcag 3900ttttagcagt ggagtggaga ctggccaaga ctctcagagg aagtgtgcac tggaaaggct 3960ggtttagccc gtgcctgata tggagacact gagcaggaca ctctggctgg gttgacagcc 4020tatagtttac atagggtgag gccacccttc atgagcagtc tcagtgacct gaagaggaag 4080ccacttcttc tgtaccgaca cggaaggtcc agtggacgga cccccagaat gctggcagtt 4140ggggtgcagg aggcattatc tcttcacaca gctttgcaga gtgagtcaag cccccatagt 4200tcaggccaaa agcactctgt ttgggatggc tctcacagtg cctcaaatct gacacaagtc 4260ttagtaagca gaagtcacaa agttgcctgt caccatcctc ctgcctacag ggaagtgggc 4320catgtctctg ccccttactc tgaggccagc tgtgggagcc gggcctgccc atgggctctc 4380tcccattgac ttctcactca cttctgaact ccgacaagca agctctcagc tcgctcaatt 4440ggcatgaagg tctgtggcta cgcagagaag tctttacaac tgtggtaaag gtcttgttgc 4500tcaagtgcca cccagcagca cggccaagcc ccctcccgtc ctttctccag acacttgggc 4560attcaagacg attccaggca gctccaaggg tgatggtgtc taacgcagaa cttcttgaag 4620aagacactga agggtctaca acagacagca gtcctcccaa gggaccccac agtcctctgt 4680agcccagcct gcctgatgaa tactcttctg gctctcgcca gccggctggg acctgtttag 4740tgacctttct gcctcagttt cctggtctgt acccgggatc atcagagatt ccatttcaag 4800aggtagtaat gaatgatatg acagaaaaca tttagagcag gggtcagtat gtacgtatga 4860gtgattactg tgagtcaggt attgtcctgt cagaacaaag cttacagcca ctcctaatct 4920ctgcagtgtt catcttggga tggccagaga atccaccaca cacctagtga ggtaacacac 4980cccagctaac tcagcaggta cagacattat ctagaagtct catggctcag agctgaattt 5040ccttctcatg acctttggcc gtgggagtga cacctcacag ctgtggtgtt ttgacaacca 5100gcagccaccg gcacacaaaa tgtgcagcca gcaacatatg aagtccaaga ggcgtctcgg 5160ctaggcctgc ccttgacccc cacctgacaa ttaaggcaag agcctgcagt ttgcatcagc 5220aacaggcagg gtcaaagttt agtcaatcaa atgttgtgta aggactcact atggctgata 5280gaggggcctg aggcctccca acattcatta acaaccacaa gttcaatcat tatctccctg 5340gagtttattg tgttaagtca gttccaaacc gtgctgacca tggctatgat ccaaaggcct 5400gccccttacg tcagaggcga gcctccgggt ccagctgagg ggcagggctg tcctcccttc 5460tatatagtat ttaaagcaag gagggcgggc taccaagcac agttggcctt ccctctggga 5520acacaccctc ggtcaacagg ggaaatccgg caaggcgctc agcgatctct gatccagacc 5580ttccaaaagg aagaaaggta ggcagggtca tttcattcac ctctccaaaa atacaatgag 5640gggcccactc atgttcttgg aaggttttcc ttctttccat ccgtcccagt aaagtaagtg 5700gagaggtttt tatgttactc cccgggtgag tacaagaata ccctgacagc catggctccc 5760tagccacttg caacccatgc aaagtctacg gaaggaccga gaaggggccc atgggtgctc 5820catggtgttc atgagtccct ttttctgttt caggtggcac cagagttcct gcctctctcc 5880acaccattgc aatt atg cct cct cag ctg cat aac ggt ctg gac ttc tct 5930 Met Pro Pro Gln Leu His Asn Gly Leu Asp Phe Ser 1 5 10gcc aag gtt atc cag ggc agc ctc gac agc ctg ccc cag gca gtg agg 5978Ala Lys Val Ile Gln Gly Ser Leu Asp Ser Leu Pro Gln Ala Val Arg 15 20 25aag ttc gtg gaa ggc aat gct cag ctg tgc cag ccg gag tat atc cac 6026Lys Phe Val Glu Gly Asn Ala Gln Leu Cys Gln Pro Glu Tyr Ile His 30 35 40atc tgc gat ggc tcc gag gag gag tac ggg cag ttg ctg gcc cac atg 6074Ile Cys Asp Gly Ser Glu Glu Glu Tyr Gly Gln Leu Leu Ala His Met 45 50 55 60cag gag gag ggt gtc atc cgc aag ctg aag aaa tat gac aac tg 6118Gln Glu Glu Gly Val Ile Arg Lys Leu Lys Lys Tyr Asp Asn Cys 65 70 75gtgagtcccc tcagccctaa ctctctggcc cacagcctcc ctaactctat cttcttagcg 6178tttggagaat gaagaccttg ccgtagcaaa cacctgagaa gcttaagaga tgccctgtga 6238ggttagcata gccagccact agattctgga taactataca aagcaactcc ttccccaggg 6298ccaggtcaca gtctagctaa tgtccacctg gtcaagctcc tgttgtcctt gtttcccgca 6358aggcttggaa ggacctggcg tgggcaagag aggtacatcc ccgaggatac cttgctgaag 6418gagtccctgt gactttttca g t tgg ctg gct ctc act gac cct cga gat gtg 6470 Trp Leu Ala Leu Thr Asp Pro Arg Asp Val 80 85gcc agg atc gaa agc aag aca gtc atc atc acc caa gag cag aga gac 6518Ala Arg Ile Glu Ser Lys Thr Val Ile Ile Thr Gln Glu Gln Arg Asp 90 95 100aca gtg ccc atc ccc aaa act ggc ctc agc cag ctg ggc cgc tgg atg 6566Thr Val Pro Ile Pro Lys Thr Gly Leu Ser Gln Leu Gly Arg Trp Met 105 110 115tcg gaa gag gac ttt gag aaa gca ttc aac gcc agg ttc cca ggg tgc 6614Ser Glu Glu Asp Phe Glu Lys Ala Phe Asn Ala Arg Phe Pro Gly Cys 120 125 130atg aaa g gtgggtgaga ccagacccca ggcctgacag tgtgctgtgt acatagttca 6671Met Lys 135tgttcctaat ggcgacctga gctgcaaagc gtggcccacg tgtgaagtgc actgtctggt 6731tctgtttcat gggtggtgac acacaggaat attaaaatgt tctctgcaag tcctggtggc 6791tcaggcctgt cagcccagac acggaagccg aggcaggagc attccaagtt tctgccagcc 6851tgagcaattt acacttggtc tcaaaagaaa aactcaaaag gtagctgtag ctatggttcc 6911gtggtagagt gtttgcctag aatttccaag gccctgggtt caatccttaa tagacaaaat 6971agaaaataca taaaatgctt cccacccatg tggatgttaa gctgcctaac aggagggtta 7031tgaaaagttt aatttcagca ctttgcagtt tccgacggcc tcctagacca gaggttcgtg 7091gccaaaaggc atgatgtgga agacacggct gtgggtacca ttaggaggag gcgccgagga 7151tgctcagtgg gcctccgtga cttcttacct atttctgcca acccgcctct gcag gc 7207 Glycgc acc atg tat gtc atc cca ttc agc atg ggg cca ctg ggc tcg ccg 7255Arg Thr Met Tyr Val Ile Pro Phe Ser Met Gly Pro Leu Gly Ser Pro 140 145 150ctg gcc aag att ggt att gaa ctg aca gac tcg ccc tat gtg gtg gcc 7303Leu Ala Lys Ile Gly Ile Glu Leu Thr Asp Ser Pro Tyr Val Val Ala 155 160 165agc atg cgg atc atg act cgg atg ggc ata tct gtg ctg gag gcc ctg 7351Ser Met Arg Ile Met Thr Arg Met Gly Ile Ser Val Leu Glu Ala Leu 170 175 180gga gat ggg gag ttc atc aag tgc ctg cac tct gtg ggg tgc cct ctc 7399Gly Asp Gly Glu Phe Ile Lys Cys Leu His Ser Val Gly Cys Pro Leu185 190 195 200ccc tta aaa a gtaagtacat tctttccaga tcgaaggtgg agggagaagt 7449Pro Leu Lystggggaaggg ttcagcgggt ggggtgctct cctggcgtgc atgaggccct gagtttgatc 7509ccagacacca aataaactga acatgctggg tcaggcctac caccccagca cgcaggagtc 7569aggagaacca gaagtttcag gtccttctca gctccgtagc tggttcgagg ccagcctgga 7629gacttgggca gggatgtgca ccacaagctc actgtggctt gcttgtttgc ag ag cct 7686 Lys Pro 205ttg gtc aac aac tgg gcc tgc aac cct gag ctg acc ctg atc gcc cac 7734Leu Val Asn Asn Trp Ala Cys Asn Pro Glu Leu Thr Leu Ile Ala His 210 215 220ctc ccg gac cgc aga gag atc atc tcc ttt gga agc gga tat ggt ggg 7782Leu Pro Asp Arg Arg Glu Ile Ile Ser Phe Gly Ser Gly Tyr Gly Gly 225 230 235aac tca cta ctc ggg aag aaa tgc ttt gcg ttg cgg atc gcc agc cgt 7830Asn Ser Leu Leu Gly Lys Lys Cys Phe Ala Leu Arg Ile Ala Ser Arg 240 245 250ctg gct aag gag gaa ggg tgg ctg gcg gag cat atg ctg gtatgtggtc 7879Leu Ala Lys Glu Glu Gly Trp Leu Ala Glu His Met Leu 255 260 265agggaaccct gggaggaaat ttggagggcc tggggtggca taggtgagct atgtcaaggt 7939tccccaacat ctggggactt gagggcagag tggagcaata ccaagttgac tctaagtacc 7999ccagcgtttg tctctttgaa agggactcag acacactggg gctgcagtga ccctggggga 8059ttttattctt tggtacccca ttagtttatc ctgatgcgtg agggatggat catggcgatc 8119tgcctttggg aagaccctac gcgctttccc agacctttgc tgcaggaagg aacacagatc 8179ttcctttctt agacaacagc accgaactca accccctccc ccacctccct cccatttatt 8239cctcagcatc ttccttttca ttttctgccc cctcccaccc tccgctagtt tggaagacag 8299tcctaggttt atgttgaaga tacacaccct tcatttctct cttttaccat atgaaggata 8359cagagtaatg ggttttattg tgagttttct acatgcatgc caaggaccag agacgactaa 8419agctgatccc gtccatccct gcag atc ctg ggc ata act aac ccc gaa ggc 8470 Ile Leu Gly Ile Thr Asn Pro Glu Gly 270 275aag aag aaa tac ctg gcc gca gcc ttc cct agt gcc tgt ggg aag act 8518Lys Lys Lys Tyr Leu Ala Ala Ala Phe Pro Ser Ala Cys Gly Lys Thr 280 285 290aac ttg gcc atg atg aac ccc agc ctg ccc ggg tgg aag gtc gaa tgt 8566Asn Leu Ala Met Met Asn Pro Ser Leu Pro Gly Trp Lys Val Glu Cys 295 300 305gtg ggc gat gac att gcc tgg atg aag ttt gat gcc caa g gtgagtcttc 8616Val Gly Asp Asp Ile Ala Trp Met Lys Phe Asp Ala Gln 310 315 320aggtctggcc aatgacagtg gtggcccctg gtgagtggct ggcttcaaac acactacacc 8676acagtctcct aaactgtcag caccgggcat tcagggtgag caaggccttc gcagtgctgt 8736cctgccggcc ttcggtgagg atcatctgga tagagaggga catgataggc tgtttgcttg 8796cacagatcca tgtttgtacg atgtggctgg ggccaccgag acaagtctat gggtaaaggc 8856acttgctgcc aagcttaatg atctgagttt gagtcccaga agcctaaatg gtcggaagag 8916agaactgatt cctgcaagtt atcctccgac ctccatatgt gtgccccaga acactcactc 8976acacacacac acacacacac acacacacac acacacacac acacactcac acacactcac 9036acatacacac acacacacac acactcacac acactcacac atacactcac acacactcac 9096acacacacac tcacatagtc acacacacat acactcacac acacactcac acacacactc 9156acatagtcac acacacacac acaccacaaa ataaataata atacttttaa aagaagagaa 9216tgtgttttag gaaccgtgaa gaagcagaaa actgcagagt ctgagctgtg gtgtgtagat 9276caaaatggct ggctgtgtag tttagggacg ggaaagaaaa agatgtgaac tttaggacat 9336gagctagcct gggcaaagct ttaagaactc tgggatgctt ggcttgcatt catacctcct 9396tctctgcctg caactttcca g gc aac tta agg gct atc aac cca gaa aac 9446 Gly Asn Leu Arg Ala Ile Asn Pro Glu Asn 325 330ggg ttt ttt gga gtt gct cct ggc acc tca gtg aag aca aat cca aat 9494Gly Phe Phe Gly Val Ala Pro Gly Thr Ser Val Lys Thr Asn Pro Asn 335 340 345gcc att aaa acc atc cag aaa aac acc atc ttc acc aac gtg gcc gag 9542Ala Ile Lys Thr Ile Gln Lys Asn Thr Ile Phe Thr Asn Val Ala Glu 350 355 360act agc gat ggg ggt gtt tac tgg gaa ggc atc gat gag ccg ctg gcc 9590Thr Ser Asp Gly Gly Val Tyr Trp Glu Gly Ile Asp Glu Pro Leu Ala 365 370 375ccg gga gtc acc atc acc tcc tgg aag aac aag gag tgg aga ccg cag 9638Pro Gly Val Thr Ile Thr Ser Trp Lys Asn Lys Glu Trp Arg Pro Gln 380 385 390gac g gtgagtccct cgagaggctg tgtgctctgg cttctgggtg ccacctatct 9692Asp395gggccatgct aaggggtatc tctctcgttc tctctcttgc ag cg gaa cca tgt gcc 9748 Ala Glu Pro Cys Ala 400cat ccc aac tcg aga ttc tgc acc cct gcc agc cag tgc ccc att att 9796His Pro Asn Ser Arg Phe Cys Thr Pro Ala Ser Gln Cys Pro Ile Ile 405 410 415gac cct gcc tgg gaa tct cca gaa gga gta ccc att gag ggt atc atc 9844Asp Pro Ala Trp Glu Ser Pro Glu Gly Val Pro Ile Glu Gly Ile Ile 420 425 430ttt ggt ggc cgt aga cct gaa g gtgaggcatc ttctattcag gctgggaacc 9896Phe Gly Gly Arg Arg Pro Glu 435tggggtgtgg cgatgcaaag aaatccagga aatatttttc caagctggtt ccaaaggatc 9956tcctcctata cttccagact aactgggcag ttttaaacat agggccagcc ttctgatcac 10016caatggcttc tgtgggtctg tgatctgagg tagctcaggt tgttctgctc cactgagtga 10076tctctctgct gtgactgccc ttagcggttt cctgttcatt gtctctctag gtgaaaggtt 10136aactcaacag aaaactcggc ttgtcagacc tagagtggct cacagctgta atcctagcac 10196ttgggtggct ggggcagggg gattgctttg agttcagggt tggcctggtc tacagagtaa 10256gctccaggct atcttgggct accgagtgaa actttctcat caaaacaaaa caagcaagga 10316aggaaggaag gaaggaagga aggaaggaag gaaggaaggg aagaaggaag gaggaaggaa 10376ggaaggaagg aaggaaggaa ggaaggaagg aaggaaggag ggaaggaaag atacagcatg 10436gttgaacagt gacgatagaa ctaagatgtc ctaagtcttt aatgatcttt gtctccctgc 10496tcaag gt gtc ccc ctt gtc tat gaa gcc ctc agc tgg cag cat ggg gtg 10545 Gly Val Pro Leu Val Tyr Glu Ala Leu Ser Trp Gln His Gly Val 440 445 450ttt gta gga gca gcc atg aga tct gag gcc aca gct gct gca gaa cac 10593Phe Val Gly Ala Ala Met Arg Ser Glu Ala Thr Ala Ala Ala Glu His455 460 465 470aag g gtgagtcaca gtctacaacc caaaccctct tcttggtgtc tgtcagggag 10647Lysggagaaatct ggcctgattg ggtcagaggt aaatggtggt ctctctgtgg cag gc aag 10705 Gly Lysatc atc atg cac gac ccc ttt gcc atg cga ccc ttc ttc ggc tac aac 10753Ile Ile Met His Asp Pro Phe Ala Met Arg Pro Phe Phe Gly Tyr Asn 475 480 485ttc ggc aaa tac ctg gcc cac tgg ctg agc atg gcc cac cgc cca gca 10801Phe Gly Lys Tyr Leu Ala His Trp Leu Ser Met Ala His Arg Pro Ala490 495 500 505gcc aag ttg ccc aag atc ttc cat gtc aac tgg ttc cgg aag gac aaa 10849Ala Lys Leu Pro Lys Ile Phe His Val Asn Trp Phe Arg Lys Asp Lys 510 515 520gat ggc aag ttc ctc tgg cca ggc ttt ggc gag aac tcc cgg gtg ctg 10897Asp Gly Lys Phe Leu Trp Pro Gly Phe Gly Glu Asn Ser Arg Val Leu 525 530 535gag tgg atg ttc ggg cgg att gaa ggg gaa gac agc gcc aag ctc acg 10945Glu Trp Met Phe Gly Arg Ile Glu Gly Glu Asp Ser Ala Lys Leu Thr 540 545 550ccc atc ggc tac atc cct aag gaa aac gcc ttg aac ctg aaa ggc ctg 10993Pro Ile Gly Tyr Ile Pro Lys Glu Asn Ala Leu Asn Leu Lys Gly Leu 555 560 565ggg ggc gtc aac gtg gag gag ctg ttt ggg atc tct aag gag ttc tgg 11041Gly Gly Val Asn Val Glu Glu Leu Phe Gly Ile Ser Lys Glu Phe Trp570 575 580 585gag aag gag gtg gag gag atc gac agg tat ctg gag gac cag gtc aac 11089Glu Lys Glu Val Glu Glu Ile Asp Arg Tyr Leu Glu Asp Gln Val Asn 590 595 600acc gac ctc cct tac gaa att gag agg gag ctc cga gcc ctg aaa cag 11137Thr Asp Leu Pro Tyr Glu Ile Glu Arg Glu Leu Arg Ala Leu Lys Gln 605 610 615aga atc agc cag atg taa atcccaatgg gggcgtctcg agagtcaccc 11185Arg Ile Ser Gln Met 620cttcccactc acagcatcgc tgagatctag gagaaagcca gcctgctcca gctttgagat 11245agcggcacaa tcgtgagtag atcagaaaag caccttttaa tagtcagttg agtagcacag 11305agaacaggct aggggcaaat aagattggga ggggaaatca ccgcatagtc tctgaagttt 11365gcatttgaca ccaatggggg ttttggttcc acttcaaggt cactcaggaa tccagttctt 11425cacgttagct gtagcagtta gctaaaatgc acagaaaaca tacttgagct gtatatatgt 11485gtgtgaacgt gtctctgtgt gagcatgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 11545gtgtgtgtgt gtgtacatgc ctgtctgtcc cattgtccac agtatattta aaacctttgg 11605ggaaaaatct tgggcaaatt tgtagctgta actagagagt catgttgctt tgttgctagt 11665atgtatgttt aaattatttt tatacaccgc ccttaccttt ctttacataa ttgaaattgg 11725tatccggacc acttcttggg aaaaaaatta caaaataaac ttttatagaa aaagtagatt 11785tcattgcctc tttttggttt ttattagaaa gggagaacac actgattaaa caccctgggg 11845ctctaatctt gctcccccgg gagcctgggg gattcacagc tgaaaggagg ggacttgtca 11905ggggccagat gtatgaggga cgggatgtgt gagggaccgg aaggagggga gaaagcagag 11965caccggcttc ccatgttata aaacattgtt accactagtt ggcgctcttt ggcagcgttt 12025cgggacaggt ctgtgcgttt gcacagctgg atctagaggg tttaaggtga attttaaaga 12085gagtttgagc ctcagggctc agccatctcc aaaagtgcag tgtgaacaag cacagg 12141 11 17 DNA Artificial Sequence PCR Primer 11atccagggca gcctcga 17 12 20 DNA Artificial Sequence PCR Primer 12agcattgcct tccacgaact 20 13 21 DNA Artificial Sequence PCR Probe 13agcctgcccc aggcagtgag g 21 14 20 DNA Artificial Sequence PCR Primer 14ggcaaattca acggcacagt 20 15 20 DNA Artificial Sequence PCR Primer 15gggtctcgct cctggaagct 20 16 27 DNA Artificial Sequence PCR Probe 16aaggccgaga atgggaagct tgtcatc 27 17 2618 DNA Mus musculus CDS (141)...(2009) 17acagttggcc ttccctctgg gaacacaccc tcggtcaaca ggggaaatcc ggcaaggcgc 60tcagcgatct ctgatccaga ccttccaaaa ggaagaaagg tggcaccaga gttcctgcct 120ctctccacac cattgcaatt atg cct cct cag ctg cat aac ggt ctg gac 170 Met Pro Pro Gln Leu His Asn Gly Leu Asp 1 5 10ttc tct gcc aag gtt atc cag ggc agc ctc gac agc ctg ccc cag gca 218Phe Ser Ala Lys Val Ile Gln Gly Ser Leu Asp Ser Leu Pro Gln Ala 15 20 25gtg agg aag ttc gtg gaa ggc aat gct cag ctg tgc cag ccg gag tat 266Val Arg Lys Phe Val Glu Gly Asn Ala Gln Leu Cys Gln Pro Glu Tyr 30 35 40atc cac atc tgc gat ggc tcc gag gag gag tac ggg cag ttg ctg gcc 314Ile His Ile Cys Asp Gly Ser Glu Glu Glu Tyr Gly Gln Leu Leu Ala 45 50 55cac atg cag gag gag ggt gtc atc cgc aag ctg aag aaa tat gac aac 362His Met Gln Glu Glu Gly Val Ile Arg Lys Leu Lys Lys Tyr Asp Asn 60 65 70tgt tgg ctg gct ctc act gac cct cga gat gtg gcc agg atc gaa agc 410Cys Trp Leu Ala Leu Thr Asp Pro Arg Asp Val Ala Arg Ile Glu Ser 75 80 85 90aag aca gtc atc atc acc caa gag cag aga gac aca gtg ccc atc ccc 458Lys Thr Val Ile Ile Thr Gln Glu Gln Arg Asp Thr Val Pro Ile Pro 95 100 105aaa act ggc ctc agc cag ctg ggc cgc tgg atg tcg gaa gag gac ttt 506Lys Thr Gly Leu Ser Gln Leu Gly Arg Trp Met Ser Glu Glu Asp Phe 110 115 120gag aaa gca ttc aac gcc agg ttc cca ggg tgc atg aaa ggc cgc acc 554Glu Lys Ala Phe Asn Ala Arg Phe Pro Gly Cys Met Lys Gly Arg Thr 125 130 135atg tat gtc atc cca ttc agc atg ggg cca ctg ggc tcg ccg ctg gcc 602Met Tyr Val Ile Pro Phe Ser Met Gly Pro Leu Gly Ser Pro Leu Ala 140 145 150aag att ggt att gaa ctg aca gac tcg ccc tat gtg gtg gcc agc atg 650Lys Ile Gly Ile Glu Leu Thr Asp Ser Pro Tyr Val Val Ala Ser Met155 160 165 170cgg atc atg act cgg atg ggc ata tct gtg ctg gag gcc ctg gga gat 698Arg Ile Met Thr Arg Met Gly Ile Ser Val Leu Glu Ala Leu Gly Asp 175 180 185ggg gag ttc atc aag tgc ctg cac tct gtg ggg tgc cct ctc ccc tta 746Gly Glu Phe Ile Lys Cys Leu His Ser Val Gly Cys Pro Leu Pro Leu 190 195 200aaa aag cct ttg gtc aac aac tgg gcc tgc aac cct gag ctg acc ctg 794Lys Lys Pro Leu Val Asn Asn Trp Ala Cys Asn Pro Glu Leu Thr Leu 205 210 215atc gcc cac ctc ccg gac cgc aga gag atc atc tcc ttt gga agc gga 842Ile Ala His Leu Pro Asp Arg Arg Glu Ile Ile Ser Phe Gly Ser Gly 220 225 230tat ggt ggg aac tca cta ctc ggg aag aaa tgc ttt gcg ttg cgg atc 890Tyr Gly Gly Asn Ser Leu Leu Gly Lys Lys Cys Phe Ala Leu Arg Ile235 240 245 250gcc agc cgt ctg gct aag gag gaa ggg tgg ctg gcg gag cat atg ctg 938Ala Ser Arg Leu Ala Lys Glu Glu Gly Trp Leu Ala Glu His Met Leu 255 260 265atc ctg ggc ata act aac ccc gaa ggc aag aag aaa tac ctg gcc gca 986Ile Leu Gly Ile Thr Asn Pro Glu Gly Lys Lys Lys Tyr Leu Ala Ala 270 275 280gcc ttc cct agt gcc tgt ggg aag act aac ttg gcc atg atg aac ccc 1034Ala Phe Pro Ser Ala Cys Gly Lys Thr Asn Leu Ala Met Met Asn Pro 285 290 295agc ctg ccc ggg tgg aag gtc gaa tgt gtg ggc gat gac att gcc tgg 1082Ser Leu Pro Gly Trp Lys Val Glu Cys Val Gly Asp Asp Ile Ala Trp 300 305 310atg aag ttt gat gcc caa ggc aac tta agg gct atc aac cca gaa aac 1130Met Lys Phe Asp Ala Gln Gly Asn Leu Arg Ala Ile Asn Pro Glu Asn315 320 325 330ggg ttt ttt gga gtt gct cct ggc acc tca gtg aag aca aat cca aat 1178Gly Phe Phe Gly Val Ala Pro Gly Thr Ser Val Lys Thr Asn Pro Asn 335 340 345gcc att aaa acc atc cag aaa aac acc atc ttc acc aac gtg gcc gag 1226Ala Ile Lys Thr Ile Gln Lys Asn Thr Ile Phe Thr Asn Val Ala Glu 350 355 360act agc gat ggg ggt gtt tac tgg gaa ggc atc gat gag ccg ctg gcc 1274Thr Ser Asp Gly Gly Val Tyr Trp Glu Gly Ile Asp Glu Pro Leu Ala 365 370 375ccg gga gtc acc atc acc tcc tgg aag aac aag gag tgg aga ccg cag 1322Pro Gly Val Thr Ile Thr Ser Trp Lys Asn Lys Glu Trp Arg Pro Gln 380 385 390gac gcg gaa cca tgt gcc cat ccc aac tcg aga ttc tgc acc cct gcc 1370Asp Ala Glu Pro Cys Ala His Pro Asn Ser Arg Phe Cys Thr Pro Ala395 400 405 410agc cag tgc ccc att att gac cct gcc tgg gaa tct cca gaa gga gta 1418Ser Gln Cys Pro Ile Ile Asp Pro Ala Trp Glu Ser Pro Glu Gly Val 415 420 425ccc att gag ggt atc atc ttt ggt ggc cgt aga cct gaa ggt gtc ccc 1466Pro Ile Glu Gly Ile Ile Phe Gly Gly Arg Arg Pro Glu Gly Val Pro 430 435 440ctt gtc tat gaa gcc ctc agc tgg cag cat ggg gtg ttt gta gga gca 1514Leu Val Tyr Glu Ala Leu Ser Trp Gln His Gly Val Phe Val Gly Ala 445 450 455gcc atg aga tct gag gcc aca gct gct gca gaa cac aag ggc aag atc 1562Ala Met Arg Ser Glu Ala Thr Ala Ala Ala Glu His Lys Gly Lys Ile 460 465 470atc atg cac gac ccc ttt gcc atg cga ccc ttc ttc ggc tac aac ttc 1610Ile Met His Asp Pro Phe Ala Met Arg Pro Phe Phe Gly Tyr Asn Phe475 480 485 490ggc aaa tac ctg gcc cac tgg ctg agc atg gcc cac cgc cca gca gcc 1658Gly Lys Tyr Leu Ala His Trp Leu Ser Met Ala His Arg Pro Ala Ala 495 500 505aag ttg ccc aag atc ttc cat gtc aac tgg ttc cgg aag gac aaa gat 1706Lys Leu Pro Lys Ile Phe His Val Asn Trp Phe Arg Lys Asp Lys Asp 510 515 520ggc aag ttc ctc tgg cca ggc ttt ggc gag aac tcc cgg gtg ctg gag 1754Gly Lys Phe Leu Trp Pro Gly Phe Gly Glu Asn Ser Arg Val Leu Glu 525 530 535tgg atg ttc ggg cgg att gaa ggg gaa gac agc gcc aag ctc acg ccc 1802Trp Met Phe Gly Arg Ile Glu Gly Glu Asp Ser Ala Lys Leu Thr Pro 540 545 550atc ggc tac atc cct aag gaa aac gcc ttg aac ctg aaa ggc ctg ggg 1850Ile Gly Tyr Ile Pro Lys Glu Asn Ala Leu Asn Leu Lys Gly Leu Gly555 560 565 570ggc gtc aac gtg gag gag ctg ttt ggg atc tct aag gag ttc tgg gag 1898Gly Val Asn Val Glu Glu Leu Phe Gly Ile Ser Lys Glu Phe Trp Glu 575 580 585aag gag gtg gag gag atc gac agg tat ctg gag gac cag gtc aac acc 1946Lys Glu Val Glu Glu Ile Asp Arg Tyr Leu Glu Asp Gln Val Asn Thr 590 595 600gac ctc cct tac gaa att gag agg gag ctc cga gcc ctg aaa cag aga 1994Asp Leu Pro Tyr Glu Ile Glu Arg Glu Leu Arg Ala Leu Lys Gln Arg 605 610 615atc agc cag atg taa atcccaatgg gggcgtctcg agagtcaccc cttcccactc 2049Ile Ser Gln Met 620acagcatcgc tgagatctag gagaaagcca gcctgctcca gctttgagat agcggcacaa 2109tcgtgagtag atcagaaaag caccttttaa tagtcagttg agtagcacag agaacaggct 2169aggggcaaat aagattggga ggggaaatca ccgcatagtc tctgaagttt gcatttgaca 2229ccaatggggg ttttggttcc acttcaaggt cactcaggaa tccagttctt cacgttagct 2289gtagcagtta gctaaaatgc acagaaaaca tacttgagct gtatatatgt gtgtgaacgt 2349gtctctgtgt gagcatgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 2409gtgtacatgc ctgtctgtcc cattgtccac agtatattta aaacctttgg ggaaaaatct 2469tgggcaaatt tgtagctgta actagagagt catgttgctt tgttgctagt atgtatgttt 2529aaattatttt tatacaccgc ccttaccttt ctttacataa ttgaaattgg tatccggacc 2589acttcttggg aaaaaaatta caaaataaa 2618 18 20 DNA Artificial Sequence Antisense Oligonucleotide 18ctcttcccgc cagcaagttt 20 19 20 DNA Artificial Sequence Antisense Oligonucleotide 19tggatgatct cgaagggaga 20 20 20 DNA Artificial Sequence Antisense Oligonucleotide 20tttctgcaga gtgctgctaa 20 21 20 DNA Artificial Sequence Antisense Oligonucleotide 21catttctgca gagtgctgct 20 22 20 DNA Artificial Sequence Antisense Oligonucleotide 22ggcatttctg cagagtgctg 20 23 20 DNA Artificial Sequence Antisense Oligonucleotide 23gaggcatttc tgcagagtgc 20 24 20 DNA Artificial Sequence Antisense Oligonucleotide 24aggaggcatt tctgcagagt 20 25 20 DNA Artificial Sequence Antisense Oligonucleotide 25tgaggaggca tttctgcaga 20 26 20 DNA Artificial Sequence Antisense Oligonucleotide 26gctgaggagg catttctgca 20 27 20 DNA Artificial Sequence Antisense Oligonucleotide 27cagctgagga ggcatttctg 20 28 20 DNA Artificial Sequence Antisense Oligonucleotide 28tgcagctgag gaggcatttc 20 29 20 DNA Artificial Sequence Antisense Oligonucleotide 29tttgcagctg aggaggcatt 20 30 20 DNA Artificial Sequence Antisense Oligonucleotide 30gttttgcagc tgaggaggca 20 31 20 DNA Artificial Sequence Antisense Oligonucleotide 31ccgttttgca gctgaggagg 20 32 20 DNA Artificial Sequence Antisense Oligonucleotide 32cgagaggttc aggccgtttt 20 33 20 DNA Artificial Sequence Antisense Oligonucleotide 33gctgtccagg cttccctgga 20 34 20 DNA Artificial Sequence Antisense Oligonucleotide 34gctgacacag ctcagcgtta 20 35 20 DNA Artificial Sequence Antisense Oligonucleotide 35tcagagccgt cacagatgtg 20 36 20 DNA Artificial Sequence Antisense Oligonucleotide 36ggcccagaag ccgcccattc 20 37 20 DNA Artificial Sequence Antisense Oligonucleotide 37ctgaggatgc cctcttcctc 20 38 20 DNA Artificial Sequence Antisense Oligonucleotide 38gcagttgtca tacttcttca 20 39 20 DNA Artificial Sequence Antisense Oligonucleotide 39ctttcgatcc tggccacatc 20 40 20 DNA Artificial Sequence Antisense Oligonucleotide 40gctcttgggt gacgataacc 20 41 20 DNA Artificial Sequence Antisense Oligonucleotide 41gctggctgag gcctgttttg 20 42 20 DNA Artificial Sequence Antisense Oligonucleotide 42atcctcctct gacatccagc 20 43 20 DNA Artificial Sequence Antisense Oligonucleotide 43ggaacctggc attgaacgct 20 44 20 DNA Artificial Sequence Antisense Oligonucleotide 44cgtacatggt gcgacctttc 20 45 20 DNA Artificial Sequence Antisense Oligonucleotide 45cagcggcccc atgctgaatg 20 46 20 DNA Artificial Sequence Antisense Oligonucleotide 46agctcgatgc cgatcttcga 20 47 20 DNA Artificial Sequence Antisense Oligonucleotide 47catgctggcc accacgtagg 20 48 20 DNA Artificial Sequence Antisense Oligonucleotide 48gacgggcgtg cccatccgcg 20 49 20 DNA Artificial Sequence Antisense Oligonucleotide 49ttgacaaact ccccatcgcc 20 50 20 DNA Artificial Sequence Antisense Oligonucleotide 50gtaaaggcag agggcacccc 20 51 20 DNA Artificial Sequence Antisense Oligonucleotide 51gttgcagggc cagttgttga 20 52 20 DNA Artificial Sequence Antisense Oligonucleotide 52gtcaggcagg tgggcgatga 20 53 20 DNA Artificial Sequence Antisense Oligonucleotide 53ccgtacccac tgccaaagga 20 54 20 DNA Artificial Sequence Antisense Oligonucleotide 54caaagcactt cttcccgagc 20 55 20 DNA Artificial Sequence Antisense Oligonucleotide 55ttcctcctct gccagccggc 20 56 20 DNA Artificial Sequence Antisense Oligonucleotide 56tatacccaga atcagcatgt 20 57 20 DNA Artificial Sequence Antisense Oligonucleotide 57ccgccaggta cttcttctca 20 58 20 DNA Artificial Sequence Antisense Oligonucleotide 58aggttggtct tcccgcaggc 20 59 20 DNA Artificial Sequence Antisense Oligonucleotide 59tccaggcaat gtcatccccg 20 60 20 DNA Artificial Sequence Antisense Oligonucleotide 60tgggttgatg gcccttaaat 20 61 20 DNA Artificial Sequence Antisense Oligonucleotide 61ctggatggtc ttgatggcat 20 62 20 DNA Artificial Sequence Antisense Oligonucleotide 62cgtcgctggt ctcggccaca 20 63 20 DNA Artificial Sequence Antisense Oligonucleotide 63cgtgatggtg acgcctgaag 20 64 20 DNA Artificial Sequence Antisense Oligonucleotide 64ggttccccat cctctgagct 20 65 20 DNA Artificial Sequence Antisense Oligonucleotide 65aatgggaaca ccttccggag 20 66 20 DNA Artificial Sequence Antisense Oligonucleotide 66gggacaccag caggtctacg 20 67 20 DNA Artificial Sequence Antisense Oligonucleotide 67aaagactcca tgttgccagc 20 68 20 DNA Artificial Sequence Antisense Oligonucleotide 68gattttgcct ttatgttctg 20 69 20 DNA Artificial Sequence Antisense Oligonucleotide 69ggtatttgcc gaagttgtag 20 70 20 DNA Artificial Sequence Antisense Oligonucleotide 70tttggctgct gggtgctggg 20 71 20 DNA Artificial Sequence Antisense Oligonucleotide 71tgtccttccg gaaccagttg 20 72 20 DNA Artificial Sequence Antisense Oligonucleotide 72ggagttctct ccaaagcctg 20 73 20 DNA Artificial Sequence Antisense Oligonucleotide 73cttttccatc gatccggttg 20 74 20 DNA Artificial Sequence Antisense Oligonucleotide 74tcaggttcag ggcatcctcc 20 75 20 DNA Artificial Sequence Antisense Oligonucleotide 75gatgctgaaa agctccatca 20 76 20 DNA Artificial Sequence Antisense Oligonucleotide 76tctcgatgtc ttccacctcc 20 77 20 DNA Artificial Sequence Antisense Oligonucleotide 77ggatctctct ctcgatttca 20 78 20 DNA Artificial Sequence Antisense Oligonucleotide 78tcaggccctg attacatctg 20 79 20 DNA Artificial Sequence Antisense Oligonucleotide 79ttaaaggtaa agcactcagg 20 80 20 DNA Artificial Sequence Antisense Oligonucleotide 80ctactgcacc ttatggattt 20 81 20 DNA Artificial Sequence Antisense Oligonucleotide 81tggcgtcaat ttgggaacac 20 82 20 DNA Artificial Sequence Antisense Oligonucleotide 82ctgctcccgg tgtggtgatg 20 83 20 DNA Artificial Sequence Antisense Oligonucleotide 83ccagtgttct gtggttctta 20 84 20 DNA Artificial Sequence Antisense Oligonucleotide 84aagatttccc ttctcaattt 20 85 20 DNA Artificial Sequence Antisense Oligonucleotide 85aatttgaaca aagtatgcat 20 86 20 DNA Artificial Sequence Antisense Oligonucleotide 86aacactgaaa agatcaatgc 20 87 20 DNA Artificial Sequence Antisense Oligonucleotide 87atatatatat acagctcaag 20 88 20 DNA Artificial Sequence Antisense Oligonucleotide 88acacacacac acacacacac 20 89 20 DNA Artificial Sequence Antisense Oligonucleotide 89tgtgcacata catgcacaca 20 90 20 DNA Artificial Sequence Antisense Oligonucleotide 90aaatatcaca cagacacatg 20 91 20 DNA Artificial Sequence Antisense Oligonucleotide 91acaaatacac ataccaaata 20 92 20 DNA Artificial Sequence Antisense Oligonucleotide 92tattttgaat aacagtacat 20 93 20 DNA Artificial Sequence Antisense Oligonucleotide 93caaaggtatt aaatatattt 20 94 20 DNA Artificial Sequence Antisense Oligonucleotide 94ggtcatcttg cccaagattt 20 95 20 DNA Artificial Sequence Antisense Oligonucleotide 95aaggaaaact agtaggtcat 20 96 20 DNA Artificial Sequence Antisense Oligonucleotide 96ttaagcacaa tattaataac 20 97 20 DNA Artificial Sequence Antisense Oligonucleotide 97tgtaaaggta aggaacaatg 20 98 20 DNA Artificial Sequence Antisense Oligonucleotide 98ccctgcctac ctttcttcct 20 99 20 DNA Artificial Sequence Antisense Oligonucleotide 99tgtatttttg gagaggtgaa 20 100 20 DNA Artificial Sequence Antisense Oligonucleotide 100aagaacatga gtgggcccct 20 101 20 DNA Artificial Sequence Antisense Oligonucleotide 101ggaaaacctt ccaagaacat 20 102 20 DNA Artificial Sequence Antisense Oligonucleotide 102cacttacttt actgggacgg 20 103 20 DNA Artificial Sequence Antisense Oligonucleotide 103gggtattctt gtactcaccc 20 104 20 DNA Artificial Sequence Antisense Oligonucleotide 104ctcttaagct tctcaggtgt 20 105 20 DNA Artificial Sequence Antisense Oligonucleotide 105ggagcttgac caggtggaca 20 106 20 DNA Artificial Sequence Antisense Oligonucleotide 106aagtcacagg gactccttca 20 107 20 DNA Artificial Sequence Antisense Oligonucleotide 107tgggccacgc tttgcagctc 20 108 20 DNA Artificial Sequence Antisense Oligonucleotide 108gaaacagaac cagacagtgc 20 109 20 DNA Artificial Sequence Antisense Oligonucleotide 109tttcttttga gaccaagtgt 20 110 20 DNA Artificial Sequence Antisense Oligonucleotide 110aggcagctta acatccacat 20 111 20 DNA Artificial Sequence Antisense Oligonucleotide 111tgcaaagtgc tgaaattaaa 20 112 20 DNA Artificial Sequence Antisense Oligonucleotide 112tgccttttgg ccacgaacct 20 113 20 DNA Artificial Sequence Antisense Oligonucleotide 113atcatgcctt ttggccacga 20 114 20 DNA Artificial Sequence Antisense Oligonucleotide 114caaactcagg gcctcatgca 20 115 20 DNA Artificial Sequence Antisense Oligonucleotide 115tggtaggcct gacccagcat 20 116 20 DNA Artificial Sequence Antisense Oligonucleotide 116accaaaggct ctgcaaacaa 20 117 20 DNA Artificial Sequence Antisense Oligonucleotide 117agggtcttcc caaaggcaga 20 118 20 DNA Artificial Sequence Antisense Oligonucleotide 118atggacggga tcagctttag 20 119 20 DNA Artificial Sequence Antisense Oligonucleotide 119gaagactcac cttgggcatc 20 120 20 DNA Artificial Sequence Antisense Oligonucleotide 120gtgtgtgtga gtgtgtgtga 20 121 20 DNA Artificial Sequence Antisense Oligonucleotide 121actctgcagt tttctgcttc 20 122 20 DNA Artificial Sequence Antisense Oligonucleotide 122ctagctcatg tcctaaagtt 20 123 20 DNA Artificial Sequence Antisense Oligonucleotide 123caagcatccc agagttctta 20 124 20 DNA Artificial Sequence Antisense Oligonucleotide 124ggtatgaatg caagccaagc 20 125 20 DNA Artificial Sequence Antisense Oligonucleotide 125agagaaggag gtatgaatgc 20 126 20 DNA Artificial Sequence Antisense Oligonucleotide 126agccagagca cacagcctct 20 127 20 DNA Artificial Sequence Antisense Oligonucleotide 127acgagagaga taccccttag 20 128 20 DNA Artificial Sequence Antisense Oligonucleotide 128catggttccg ctgcaagaga 20 129 20 DNA Artificial Sequence Antisense Oligonucleotide 129gatgcctcac cttcaggtct 20 130 20 DNA Artificial Sequence Antisense Oligonucleotide 130agatcctttg gaaccagctt 20 131 20 DNA Artificial Sequence Antisense Oligonucleotide 131agttttctgt tgagttaacc 20 132 20 DNA Artificial Sequence Antisense Oligonucleotide 132ttccttcctt ccttcctcct 20 133 20 DNA Artificial Sequence Antisense Oligonucleotide 133ataaaagttt attttgtaat 20 134 20 DNA Artificial Sequence Antisense Oligonucleotide 134ctataaaagt ttattttgta 20 135 20 DNA Artificial Sequence Antisense Oligonucleotide 135gtgttcccag agggaaggcc 20 136 20 DNA Artificial Sequence Antisense Oligonucleotide 136tgagcgcctt gccggatttc 20 137 20 DNA Artificial Sequence Antisense Oligonucleotide 137ctggtgccac ctttcttcct 20 138 20 DNA Artificial Sequence Antisense Oligonucleotide 138ttgcaatggt gtggagagag 20 139 20 DNA Artificial Sequence Antisense Oligonucleotide 139gcataattgc aatggtgtgg 20 140 20 DNA Artificial Sequence Antisense Oligonucleotide 140ctgaggaggc ataattgcaa 20 141 20 DNA Artificial Sequence Antisense Oligonucleotide 141agatgtggat atactccggc 20 142 20 DNA Artificial Sequence Antisense Oligonucleotide 142atgacaccct cctcctgcat 20 143 20 DNA Artificial Sequence Antisense Oligonucleotide 143agccagccaa cagttgtcat 20 144 20 DNA Artificial Sequence Antisense Oligonucleotide 144cttgggtgat gatgactgtc 20 145 20 DNA Artificial Sequence Antisense Oligonucleotide 145tctctgctct tgggtgatga 20 146 20 DNA Artificial Sequence Antisense Oligonucleotide 146ccagctggct gaggccagtt 20 147 20 DNA Artificial Sequence Antisense Oligonucleotide 147tttctcaaag tcctcttccg 20 148 20 DNA Artificial Sequence Antisense Oligonucleotide 148caccctggga acctggcgtt 20 149 20 DNA Artificial Sequence Antisense Oligonucleotide 149atggtgcggc ctttcatgca 20 150 20 DNA Artificial Sequence Antisense Oligonucleotide 150tgaatgggat gacatacatg 20 151 20 DNA Artificial Sequence Antisense Oligonucleotide 151tgctgaatgg gatgacatac 20 152 20 DNA Artificial Sequence Antisense Oligonucleotide 152ctccttagcc agacggctgg 20 153 20 DNA Artificial Sequence Antisense Oligonucleotide 153cttaagttgc cttgggcatc 20 154 20 DNA Artificial Sequence Antisense Oligonucleotide 154aaaaacccgt tttctgggtt 20 155 20 DNA Artificial Sequence Antisense Oligonucleotide 155atttggattt gtcttcactg 20 156 20 DNA Artificial Sequence Antisense Oligonucleotide 156agtctcggcc acgttggtga 20 157 20 DNA Artificial Sequence Antisense Oligonucleotide 157aaacaccccc atcgctagtc 20 158 20 DNA Artificial Sequence Antisense Oligonucleotide 158catcgatgcc ttcccagtaa 20 159 20 DNA Artificial Sequence Antisense Oligonucleotide 159caaagatgat accctcaatg 20 160 20 DNA Artificial Sequence Antisense Oligonucleotide 160tctgcagcag ctgtggcctc 20 161 20 DNA Artificial Sequence Antisense Oligonucleotide 161atgatcttgc ccttgtgttc 20 162 20 DNA Artificial Sequence Antisense Oligonucleotide 162gtatttgccg aagttgtagc 20 163 20 DNA Artificial Sequence Antisense Oligonucleotide 163ggccatgctc agccagtggg 20 164 20 DNA Artificial Sequence Antisense Oligonucleotide 164ccagaggaac ttgccatctt 20 165 20 DNA Artificial Sequence Antisense Oligonucleotide 165tccgcccgaa catccactcc 20 166 20 DNA Artificial Sequence Antisense Oligonucleotide 166gtagccgatg ggcgtgagct 20 167 20 DNA Artificial Sequence Antisense Oligonucleotide 167tcaatttcgt aagggaggtc 20 168 20 DNA Artificial Sequence Antisense Oligonucleotide 168gattctctgt ttcagggctc 20 169 20 DNA Artificial Sequence Antisense Oligonucleotide 169attgggattt acatctggct 20 170 20 DNA Artificial Sequence Antisense Oligonucleotide 170aaaggtgctt ttctgatcta 20 171 20 DNA Artificial Sequence Antisense Oligonucleotide 171tattaaaagg tgcttttctg 20 172 20 DNA Artificial Sequence Antisense Oligonucleotide 172tggaaccaaa acccccattg 20 173 20 DNA Artificial Sequence Antisense Oligonucleotide 173ttttctgtgc attttagcta 20 174 20 DNA Artificial Sequence Antisense Oligonucleotide 174gctcaagtat gttttctgtg 20 175 20 DNA Artificial Sequence Antisense Oligonucleotide 175cacatgctca cacagagaca 20 176 20 DNA Artificial Sequence Antisense Oligonucleotide 176tacaaatttg cccaagattt 20 177 20 DNA Artificial Sequence Antisense Oligonucleotide 177aaacatacat actagcaaca 20

Claims

1. An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 18, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 62, 65, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 86, 87, 88, 94, 95, 108, 110, 113, 114, 121, 125, 140, 145, 157, 169, 173, 174 or 176 which inhibits the expression of PEPCK-cytosolic.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

4. The antisense compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

6. The antisense compound of claim 5 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.

7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

8. The antisense compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

9. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. A method of inhibiting the expression of PEPCK-cytosolic in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of PEPCK-cytosolic is inhibited.